Novel excitatory amino acid glutamate transport modulators and methods of use thereof

By developing compounds that can activate or upregulate the activity of GLT-1 protein, the problem of regulating glutamate transporter activity has been solved, enabling effective treatment of neurological diseases and reducing side effects.

CN118946550APending Publication Date: 2024-11-12DREXEL UNIV
View PDF 28 Cites 0 Cited by

Patent Information

Application Number
CN202380029859.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-25
Filing Date
2023-01-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively regulate the activity of glutamate transporters, leading to abnormally high extracellular glutamate concentrations and triggering a series of neurological diseases and disorders. Existing drugs also have significant side effects or require preventative use.

Method used

A class of compounds was developed that, by binding to the GLT-1 protein, activate or upregulate its activity, increase the rate of glutamate transport, reduce the concentration of glutamate near the synapse, and decrease excitotoxicity.

Benefits of technology

It effectively reduces extracellular glutamate concentration, improves symptoms of neurological diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease, reduces side effects, and provides rapid neuroprotective effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005056716930000021
    Figure BDA0005056716930000021
  • Figure BDA0005056716930000141
    Figure BDA0005056716930000141
  • Figure BDA0005056716930000181
    Figure BDA0005056716930000181
Patent Text Reader

Abstract

Described herein are compounds useful as glutamate transport modulators, such as GLT-1 modulators. Also described herein is a method of increasing glutamate clearance by a cell containing GLT-1, the method comprising contacting the cell with a compound contemplated herein. Also described herein is a method of preventing, treating and / or ameliorating a neurological disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound contemplated herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 302,758, filed on January 25, 2022, entitled “NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME,” the disclosure of which is incorporated herein by reference in its entirety. Background Art

[0003] Glutamate is the predominant excitatory amino acid neurotransmitter in the mammalian central nervous system (CNS) and is essential for normal brain function including cognition, memory, learning, developmental plasticity, and long-term delays. Termination of glutamate neurotransmission is achieved by rapid uptake of released glutamate by presynaptic and astrocytic sodium-dependent transporters. There are five subtypes of excitatory amino acid transporters or glutamate transporters: EAAT1 or GLAST, EAAT2 or GLT-1, EAAT3 or EAAC1, EAAT4, and EAAT5. The major regulator of extracellular glutamate levels in the brain is EAAT2, which is expressed in astrocytes and is responsible for approximately 90% of the total glutamate uptake in the CNS and accounts for approximately 1% of the total brain protein in the CNS.

[0004] Glutamate transport is a multistep process that utilizes + and K + The energy of the electrochemical gradient is used to move glutamate against the concentration gradient. The rate-limiting step in this cycle involves K + The transport of glutamate and the redirection of transporters to allow access to new substrate molecules in the synaptic cleft are fundamentally dependent on the glutamate transporter. Despite the discovery of crystal structures of several bacterial homologues of the glutamate transporter Glt(ph), no rationally designed activators of the transporter have been discovered to date.

[0005] Ischemic events in humans and animals result in acute and sustained increases in extracellular glutamate concentrations, suggesting that glutamate transporters are unable to clear glutamate in a timely manner. In fact, glutamate transporter dysfunction is often part of the initiating event or cascade leading to brain damage. Reduced EAAT2 activity increases susceptibility to seizures and vulnerability to ischemia. As extracellular glutamate levels remain elevated, glutamate receptors become overactivated, which results in Ca 2+ influx, and the activation of a cascade of phospholipases, endo- and proteases (such as calpains) that can lead to apoptotic or necrotic cell death.

[0006] Glutamate excitotoxicity has been implicated in acute conditions such as brain trauma, hyperexcitability, seizures and epilepsy, stroke, brain and retinal ischemia, and chronic conditions such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Huntington's disease, schizophrenia, neuropathic pain, alcohol and drug addiction, HIV-associated neurocognitive disorders, depression, learning and memory, and impulsive and compulsive drug-taking behaviors associated with neurological and neurodegenerative disorders. Furthermore, ischemic events in humans and animals result in acute and sustained increases in extracellular glutamate concentrations, suggesting a lack of proper clearance by glutamate transporters. Indeed, glutamate transporter dysfunction is often part of the initiating event or cascade leading to brain injury.

[0007] Reduced EAAT2 activity results in increased susceptibility to seizures and vulnerability to damage caused by ischemia. Knockout of the EAAT2 gene following brain injury in mice resulted in increased damage compared to wild-type mice, as well as controlled cortical effects in rats. Furthermore, a transgenic approach to EAAT2 overexpression in double transgenic mice generated by crossing an ALS mouse model with a mouse model overexpressing EAAT2 produced animals that showed delayed decline in grip strength, motor neuron loss, and increased life expectancy.

[0008] Several classes of compounds that target various stages of these processes, such as NMDA receptor antagonists and calcium influx inhibitors, have alleviated cell damage and neurological deficits to some extent, but their clinical application is limited due to significant side effects. Transcriptional or translational upregulators of EAAT2, such as GPI-1046, ceftriaxone, hamiltona, and pyridazine derivatives, can play a neuroprotective role by selectively enhancing the expression of EAAT2. However, these compounds must be administered prophylactically to be neuroprotective, and therefore they are of little clinical significance for acute conditions. Some compounds with neuroprotective properties, such as MS-153, riluzole, guanosine, and nicergoline, can acutely stimulate glutamate uptake by indirectly modulating the activity of transporters, but they are all nonspecific and cause many side effects.

[0009] There is a need in the art to identify molecules that modulate glutamate transmission and can be used to treat, ameliorate and / or prevent diseases or disorders caused, induced or characterized by abnormally reduced glutamate transporter activity or abnormally elevated extracellular CNS glutamate concentrations in a subject. The present invention can meet this need. Summary of the invention

[0010] In some aspects, the present invention relates to the following non-limiting embodiments:

[0011] In some embodiments, the present invention is directed to a compound.

[0012] In some embodiments, the compound is of formula (I):

[0013]

[0014] or a salt, solvate, enantiomer, diastereomer, isotopically labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof,

[0015] In some embodiments, A is a bond or where * is the bond to the carbonyl group.

[0016] In some embodiments, R1-R 13 Each is independently selected from H, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 heteroalkyl and C3-C 10 Cycloalkyl, wherein alkyl, alkoxy, heteroalkyl and cycloalkyl are each independently optionally substituted with at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy.

[0017] In some embodiments, R 14 is H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 10 Cycloalkyl and phenyl, wherein alkyl, alkoxy, heteroalkyl and cycloalkyl are independently optionally substituted with at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy.

[0018] In some embodiments, R 15 is phenyl optionally substituted by at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy.

[0019] In some embodiments, the compounds prevent, treat and / or ameliorate nervous system disorders.

[0020] In some embodiments, one or more of R1-R5 is C1-C6 alkoxy.

[0021] In some embodiments, R 14 is optionally substituted phenyl.

[0022] In some embodiments, the compound is at least one selected from the group consisting of: N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide (GT467 or GTS467) and N-(4-methoxyphenyl)-2-oxo-2-(4-phenylpiperazin-1-yl)acetamide (GT511), or a salt, solvate, enantiomer, diastereomer, isotope-labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof.

[0023] In some embodiments, the compound is (R)-N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide or (S)-N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide or a salt, solvate, isotope-labeled derivative or tautomer thereof.

[0024] In some embodiments, the present invention relates to a method of increasing the activity of a GLT-1 protein.

[0025] In some embodiments, the method comprises contacting a GLT-1 protein with a compound described herein.

[0026] In some embodiments, the GLT-1 protein is an isolated protein or a protein expressed in a cell.

[0027] In some embodiments, the GLT-1 protein is on the surface of an astrocyte.

[0028] In some embodiments, the astrocyte is in the central nervous system (CNS) of the subject.

[0029] In some embodiments, the subject suffers from a disorder associated with elevated extracellular glutamate concentrations at synapses of the CNS. In some embodiments, the method comprises administering to the subject an effective amount of a compound herein.

[0030] In some embodiments, conditions associated with elevated extracellular glutamate concentrations at synapses of the CNS include at least one neurological disorder selected from Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse behaviors, and learning and memory impairments associated with neurological and neuropsychiatric disorders.

[0031] In some embodiments, the present invention relates to methods of preventing, treating and / or ameliorating a nervous system disorder in a subject in need thereof.

[0032] In some embodiments, the method comprises administering to the subject an effective amount of a compound herein.

[0033] In some embodiments, the nervous system disorder comprises at least one selected from Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse behaviors, and / or learning and memory impairment associated with nervous system and neuropsychiatric disorders.

[0034] In some embodiments, the compound is administered to a subject as a pharmaceutical composition.

[0035] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0036] In some embodiments, the method further comprises administering to the subject an additional therapeutic agent.

[0037] In some embodiments, the compound and the additional therapeutic agent are co-administered to a subject.

[0038] In some embodiments, the compound and the additional therapeutic agent are co-formulated.

[0039] In some embodiments, the subject is a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] The following detailed description of exemplary embodiments will be better understood when read in conjunction with the accompanying drawings. For illustration purposes, non-limiting embodiments are shown in the accompanying drawings. However, it should be understood that the present description is not limited to the precise arrangements and tools of the embodiments shown in the accompanying drawings.

[0041] Figure 1 It is a non-limiting mechanism of action of the GLT-1 regulator proposed according to some embodiments. Specifically, under normal circumstances, glutamate (Glu) is released from neuronal terminals and taken up by GLT-1 (also referred to as EAAT2) on astrocytes. Glu is converted into glutamine (Gln) in astrocytes and transported out of astrocytes. Gln is then wrapped by VGlut2 in neurons (not shown). In disease conditions such as Parkinson's disease, the loss of dopamine neurons (DA neurons) can lead to the generation and release of excessive Glu and the downregulation of GLT-1 (EAAT2). The GLT-1 regulator described herein can activate GLT-1 (EAAT2) and increase the uptake of Glu by astrocytes.

[0042] Figure 2 Described are the results of glutamate uptake assay testing of nine (9) novel compounds as well as the parent compound according to some embodiments.

[0043] Figure 3 The chemical structures of two exemplary GLT-1 modulators according to some embodiments are shown. The EC of the exemplary GLT-1 modulators is also shown. 50 value.

[0044] Figure 4A and 4BDepicted are the pharmacokinetic profiles of two exemplary GLT-1 modulators in rat plasma when administered intraperitoneally (IP), intravenously (IV), or orally (PO), according to some embodiments. Figure 4A The pharmacokinetic characteristics of GT467 were described. Figure 4B The pharmacokinetic characteristics of GT511 were described.

[0045] Figure 5A and 5B Depicted are the pharmacokinetic profiles of two exemplary GLT-1 modulators in rat brain when administered intraperitoneally (IP), intravenously (IV), or orally (PO), according to some embodiments. Figure 5A The pharmacokinetic characteristics of GT467 were described. Figure 5B The pharmacokinetic characteristics of GT511 were described.

[0046] Figures 6A-6C It is shown that, according to some embodiments, exemplary GLT-1 modulators improve locomotor activity in a Huntington's disease model of Drosophila. Fig. 6A Certain aspects of a locomotor assay for detecting locomotor activity are illustrated. Fig. 6A As shown, a Drosophila larva was placed on the center line of the dish and the number of lines the larva crossed within 30 seconds was counted. Figure 6B and 6C Depicted are the results of locomotion assays in wild-type flies ("WT") and flies from a Huntington's disease model treated with vehicle ("Veh") or varying concentrations of two exemplary GLT-1 modulators. Figure 6B The results of GT467 treatment are described. Figure 6C The results of the GT511 treatment are described.

[0047] Figures 7A-7D It is shown that, according to some embodiments, exemplary GLT-1 modulators improve learning and memory in a Drosophila model of Huntington's disease. Fig. 7A Illustration of some aspects of larval olfactory associative learning used to test learning and memory. Fig. 7A Larvae were trained with either a reinforcer solution containing sucrose ("LIN / SUC") or a distilled water control ("LIN / DW"). The trained larvae were then transferred to a dish with the test odorant on one side and the control on the opposite side. Larvae that associated with the odorant in less than 1 min and crossed to the odorant side were classified as high performers, and larvae that crossed to the odorant side between 1-3 min were classified as low performers, and larvae that did not associate were called non-performers. High performers ( Figure 7B ), low performers ( Figure 7C ) and non-performers ( Fig.7D)’s ΔRI (difference between LIN / SUC and LIN / DW performance scores).

[0048] Figures 8A-8B It is shown that according to some embodiments, exemplary GLT-1 modulators improve the life span of fruit flies in Huntington's disease models. Life span determination is performed according to Romero et al., Neuron, 57 (1), 27-40 and Linford et al., JoVE (Journal of Visualized Experiments), (71). In short, 100 adult flies of wild type and HTT phenotype (male and female) are collected in each designated tube and fed with food containing a specific concentration of drug. Flies are moved into new bottles containing fresh food and drugs every 2-3 days. Dead flies are removed and the number of flies that survive each replacement is recorded. Coordination is maintained until the last fly, and the data are plotted as a survival curve. Fig. 8A Some aspects of life span determination are illustrated. Figure 8B Results of lifespan assays are depicted.

[0049] Figures 9A-9B It was shown that, according to some embodiments, exemplary GLT-1 modulators rescued motor deficits and improved performance on memory tasks in a mouse model of Huntington's disease (R6 / 2 mice). Fig.9A The results of the exercise test are depicted. Fig.9A In the locomotor test, wild-type mice and R6 / 2 mice treated with vehicle or different doses of GTS467 (2, 4 and 10 mg / kg) or ceftriaxone (200 mg / kg) were subjected to an open field test to assess their locomotor ability in a 44×44 cm and 43×43 cm square open field arena. Animals were placed individually in the open field arena and behavior was recorded under dim light and low noise conditions for 5 minutes. The behavior of the animals was recorded using an overhead camera, and the distance moved was recorded and quantified using Noldus ethovision XT-14 software. Fig. 9B Depicts the results of a memory task test. Fig. 9BTo test for memory impairment, a novel object recognition assay was performed. A 44 × 44 cm square open field space was used for this test at weeks 12 and 15. Behavioral assessments were performed in two groups with an equal number of animals in each group. The day before the start of the test, the animals were habituated for 5 min, then familiarized with a similar object for 10 min and tested with a different object for 10 min on the second day. The behavior of the animals was recorded using an overhead camera under dim light and low noise conditions. The cumulative duration of the two objects, the total object exploration time (seconds), and the distance traveled (cm) were quantified using Noldus ethovision XT 14 software.

[0050] Fig.10 is a schematic diagram illustrating that, according to some embodiments, GTS467 activates EAAT2 and modulates glutamate neurotransmitters to reduce excitotoxicity.

[0051] Fig.11 is a schematic diagram illustrating certain aspects of the experimental design of Example 2, according to some embodiments.

[0052] Fig.12 Listed is a training schedule and success criteria for a 5CSRTT (5-Choice Serial Reaction Time Task) assay according to some embodiments.

[0053] Fig.13 : Schematic diagram of a 5CSRTT assay, according to some embodiments. Rats are trained to receive food rewards when they correctly poke their nose in response to a signal light (arrows connecting 1 and 3 show correct trials). Incorrect trials (arrows connecting 2 / 3 and 1) or omissions (arrows connecting 4 with other boxes) result in timeouts, which are represented by darkness and no cue lights. The interval between trial resets is variable. Nose pokes during the inter-trial interval (ITI) are recorded as premature responses (PMRs), representing impulsive behavior.

[0054] Figures 14A-14C : 5CSRTT results according to some embodiments. Premature responses (PMR) of PD rats treated with GTS467 (GTS) were significantly reduced compared with the saline group ( Fig.14A A). In addition, the GTS467 group made significantly more correct choices (CR) compared to the saline group ( Fig. 14B ) and significantly reduced omissions (OM) ( Fig. 14C ), *P<0.05.

[0055] Figures 15A-15B : According to some embodiments, the frequency and time spent by PD rats treated with saline or GTS467 in the open and closed arms of the EPM. The results showed that there were significant differences in the frequency of entering the open arms for all animal groups ( Fig.15A ), but the time spent in the open arms did not change significantly ( Fig. 15B ), which indicates that the drug did not induce any anxiety. For the saline group and GTS467 group, respectively, * # P<0.05.

[0056] Fig.16 : Representative immunoblots of EAAT2, NR2A, NR2B, NR1 and loading control β-actin in the cortex (CRTX) and striatum (STR) from PD rats after behavioral studies, according to some embodiments.

[0057] Figure 17: Quantification of immunoblots showing that, in addition to NR1 being reduced in CRTX, expression was significantly increased after GTS467 treatment (*P<0.05, **P<0.01), according to some embodiments. Left panel - CRTX, right panel - STR. DETAILED DESCRIPTION

[0058] The following disclosure provides many different embodiments or examples for realizing the different features of the provided subject matter. Specific examples of components and arrangements are described below to simplify the disclosure. Of course, these are merely examples and are not intended to be limited. For example, in the following description, a first feature may be formed on or on a second feature and may include an embodiment in which the first feature and the second feature are directly contacted to form, and may also include an embodiment in which additional features are formed between the first feature and the second feature so that the first and second features may not be directly contacted. In addition, the disclosure may repeat reference numerals and / or letters in various embodiments. This repetition is for the purpose of simplicity and clarity, and does not itself determine the relationship between the various embodiments and / or configurations discussed.

[0059] Small molecule therapies currently available for the treatment of glutamate disorders act primarily on neuronal targets, such as metabotropic glutamate receptors (mGluRs), N-methyl-D-aspartate receptors (NMDA receptors or NMDARs), and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA receptors or AMPARs). However, mGluRs, NMDARs, and AMPARs are present in neurons and are directly involved in synaptic transmission. Therefore, modulating the activity of these neuronal targets often results in undesirable, sometimes severe side effects that limit the utility of these small molecule therapies for the treatment of various glutamate disorders.

[0060] GLT-1 (glutamate transporter 1, also known as excitatory amino acid transporter 2 or EAAT2) is a transporter that clears the excitatory neurotransmitter glutamate from the extracellular space at synapses. GLT-1 is responsible for nearly 85% of all glutamate transmission in the brain. Unlike the traditional neuronal targets mGluRs, NMDARs, and AMPARs, GLT-1 is primarily distributed on astrocytes (although a small portion of the protein is distributed on neurons in a region-specific manner).

[0061] The studies described herein ("the present study") identified novel modulators of GLT-1. The small molecule modulators identified in the present study upregulate GLT-1 by increasing the activity of glutamate transporters. Activated GLT-1 in cells increases the transport rate of glutamate, thereby transporting extracellular glutamate into the cell at an increased rate. Since GLT-1 is primarily present on astrocytes, upregulation of GLT-1 by the GLT-1 modulators described herein may allow astrocytes to clear excess glutamate and reduce glutamate concentrations near synapses.

[0062] Reference Figure 1 , activation of GLT-1 (also known as EAAT2) on astrocytes allows excess glutamate (which can cause neurological disorders) to enter astrocytes via activated GLT-1. Glutamate is then converted to glutamine in astrocytes by enzymes such as glutamine synthetase (GS). In neurodegenerative diseases, this can improve symptoms such as motor deficits and treat chorea and cognitive impairment. In addition, due to the limited expression of GLT-1 in neurons, the GLT-1 activators found in this study can reduce excitotoxicity without directly affecting synaptic transmission at presynaptic and postsynaptic sites. Since the GLT-1 activators of the present invention have the ability to clear excess glutamate without interfering with neuronal glutamate receptors, these GLT-1 activators have significant advantages in efficacy and reducing side effects.

[0063] Therefore, in some aspects, the present invention relates to a compound, wherein the compound is a compound represented by formula (I) or a salt, solvate, enantiomer, diastereomer, isotopically labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof: In some embodiments, the compounds of the invention are useful as glutamate transport modulators, such as GLT-1 modulators.

[0064] In some aspects, the present invention relates to a method for increasing the activity of GLT-1, which comprises contacting GLT-1 with a compound of formula (I) or a salt, solvate, enantiomer, diastereomer, isotope-labeled derivative, tautomer or geometric isomer, or a mixture thereof.

[0065] In some aspects, the present invention relates to a method for increasing glutamate clearance by a cell containing GLT-1. The method comprises contacting a cell containing GLT-1 with a compound of formula (I), or a salt, solvate, enantiomer, diastereomer, isotope-labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof.

[0066] In some aspects, the present invention relates to a method for preventing, treating and / or improving a nervous system disorder in a subject in need thereof. The method comprises administering to the subject an effective amount of a compound of formula (I) or a salt thereof, a solvate, an enantiomer, a diastereomer, an isotope-labeled derivative, a tautomer or a geometric isomer, or a mixture thereof. In some embodiments, nervous system disorders include Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy and / or schizophrenia, compulsive and impulsive drug and alcohol abuse behaviors, and learning and memory impairment associated with nervous system and neuropsychiatric disorders.

[0067] definition

[0068] As used herein, each of the following terms has the meaning associated with it in this section. Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as those of ordinary skill in the art to which the present disclosure belongs. Generally, the nomenclature used herein and the laboratory procedures in animal pharmacology, pharmaceutical science, peptide chemistry, and organic chemistry are well-known and commonly used in the art. It should be understood that the order of steps or the order for performing certain actions is unimportant as long as the present teaching remains operable. Any use of section headings is intended to assist in reading the document and should not be construed as restrictive; information associated with section headings may occur within or outside of that particular section. All publications, patents, and patent documents cited in this document are incorporated herein by reference in their entirety, as if they were individually incorporated by reference.

[0069] In the present application, when a description is made that an element or component is included in a list of listed elements or components and / or selected from a list of listed elements or components, it should be understood that the element or component can be any one of the listed elements or components and can be selected from two or more of the listed elements or components.

[0070] In the methods described herein, actions may be performed in any order unless a time or sequence of operations is explicitly stated. In addition, specified actions may be performed simultaneously unless explicit declarative language states that they are performed separately. For example, a claimed X action and a claimed Y action may be performed simultaneously in a single operation, and the resulting process will fall within the literal scope of the claimed process.

[0071] As used herein, the terms "a", "an" or "the" are used to include one or more, unless the context clearly indicates otherwise. The term "or" is used to represent a non-exclusive "or", unless otherwise stated. The statement "at least one of A and B" or "at least one of A or B" has the same meaning as "A, B, or A and B".

[0072] When "about" is used herein to refer to a measurable value such as an amount, a time duration, etc., it is intended to encompass variations of ±20% or ±10%, in some embodiments ±5%, in some embodiments ±1%, and in some embodiments ±0.1% from the specified value, as such variations are suitable for performing the disclosed methods.

[0073] As used herein, the term "activator" or "stimulator" or "upregulator" as applied to a glutamate transporter refers to a compound that interacts with a glutamate transporter (such as a glutamate transporter in a cell or subject) and increases, upregulates, enhances and / or restores the activity of the transporter. In certain embodiments, a glutamate transporter activator can modulate the extracellular glutamate concentration in a cell or a subject in need thereof. Normal activity levels of glutamate transporters can be determined by examining the cell or subject for normally functioning glutamate transporters. Abnormally reduced glutamate transporter activity or abnormally elevated extracellular CNS glutamate concentrations can result in a disease or disorder in a subject. In one aspect, glutamate transporter dysfunction is often part of the initiating event or cascade leading to brain injury, and reduced glutamate transport activity results in increased susceptibility to epileptic seizures and increased susceptibility to injury caused by ischemia.

[0074] As used herein, unless otherwise indicated, the term "alkoxy" used alone or in combination with other terms refers to an alkyl group with a specified number of carbon atoms attached to the remainder of the molecule via an oxygen atom as defined above, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy (isopropoxy) and higher homologues and isomers. Illustrative examples are C1-C3 alkoxy, particularly ethoxy and methoxy.

[0075] As used herein, unless otherwise indicated, the term "alkyl" by itself or as part of another substituent refers to a straight or branched chain hydrocarbon (i.e., C 1-6alkyl, particularly ethyl, methyl, isopropyl, isobutyl, n-pentyl, n-hexyl and cyclopropylmethyl. C0 alkyl corresponds to a bond.

[0076] As used herein, unless otherwise indicated, the term "alkenyl" used alone or in combination with other terms refers to a stable monounsaturated or diunsaturated straight or branched hydrocarbon radical having a specified number of carbon atoms. Examples include ethenyl, propenyl (or allyl), butenyl (crotyl), isopentenyl, butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and higher homologs and isomers. An example of a functional group representing an alkene is -CH2-CH=CH2.

[0077] As used herein, unless otherwise indicated, the term "alkynyl", alone or in combination with other terms, refers to a straight or branched chain hydrocarbon residue having a carbon-carbon triple bond and having the specified number of carbon atoms (i.e., C1-C 10 represents one to ten carbon atoms), and includes straight chain, branched chain or cyclic substituents.

[0078] As used herein, unless otherwise indicated, the term "cycloalkyl" by itself or as part of another substituent refers to a cyclic hydrocarbon having a specified number of carbon atoms (i.e., C3-C6 refers to a cyclic group including a cyclic group consisting of 3 to 6 carbon atoms) and includes straight chain, branched or cyclic substituents. Examples of (C3-C6) cycloalkyls are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkyl ring may be optionally substituted. Non-limiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulenyl; bicyclo[6.2.0]decyl, decahydronaphthyl, and dodecahydro-1H-fluorenyl. The term "cycloalkyl" also includes bicyclic hydrocarbon rings, non-limiting examples of which include bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.

[0079] As used herein, unless otherwise stated, the term "halo" or "halogen" by itself or as part of another substituent refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.

[0080] As used herein, the term "substituted" refers to an atom or group of atoms that has replaced a hydrogen as a substituent attached to another group.

[0081] As used herein, the term "substituted alkyl", "substituted cycloalkyl", "substituted alkenyl" or "substituted alkynyl" refers to an alkyl, cycloalkyl, alkenyl or alkynyl group as defined elsewhere herein, which is independently selected from halogen, -OH, alkoxy, tetrahydro-2-H-pyranyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl), 1-methyl-imidazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, -C(=O)OH, -C(=O)O(C1-C6)alkyl, trifluoromethyl, -C≡N, -C(= -C(=O)NH2, -C(=O)NH(C1-C6)alkyl, -C(=O)N((C1-C6)alkyl)2, -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, -C(=NH)NH2 and -NO2 are substituted with one, two or three substituents, and in some embodiments contain one or two substituents independently selected from halogen, -OH, alkoxy, -NH2, trifluoromethyl, -N(CH3)2 and -C(=O)OH, which are independently selected from halogen, alkoxy and -OH in some embodiments. Examples of substituted alkyl include, but are not limited to, 2,2-difluoropropyl, 2-carboxycyclopentyl and 3-chloropropyl.

[0082] Whenever any of the terms or their prefix roots appear in the name of a substituent, the name should be interpreted as including those limitations provided herein. For example, whenever the term "alkyl" or "aryl" or any of their prefix roots appear in the name of a substituent (e.g., arylalkyl, alkylamino), the name should be interpreted as including those limitations given elsewhere herein for "alkyl" and "aryl", respectively.

[0083] In certain embodiments, substituents of compounds are disclosed in groups or ranges. It is specifically intended that the description includes each and every individual subcombination of the members of these groups and ranges. For example, the term "C 1-6The term “alkyl” is expressly intended to disclose individually C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 alkyl.

[0084] As used herein, the term "aromatic" refers to a carbon or heterocyclic ring having one or more polyunsaturated rings and having aromatic character, ie, having (4n+2) delocalized π (pi) electrons (where 'n' is an integer).

[0085] As used herein, unless otherwise indicated, the term "aryl" used alone or in combination with other terms refers to a carbocyclic aromatic system containing one or more rings (usually one, two or three rings), wherein these rings can be linked together in a side chain manner, such as biphenyl, or can be fused, such as naphthalene. Examples include phenyl, anthracenyl and naphthyl. Illustrative examples are phenyl and naphthyl or phenyl.

[0086] The term "container" includes any receptacle for holding a pharmaceutical composition. For example, in one embodiment, the container is a package comprising a pharmaceutical composition. In other embodiments, the container is not a package comprising a pharmaceutical composition, that is, the container is a receptacle, such as a box or a vial comprising a packaged pharmaceutical composition or an unpackaged pharmaceutical composition and instructions for use of the pharmaceutical composition. In addition, packaging technology is well known in the art. It should be understood that the instructions for use of the pharmaceutical composition may be included in the package containing the pharmaceutical composition, and therefore, the instructions form an increased functional relationship with the packaged product. However, it should be understood that the instructions may include information about the ability of the compound to perform its intended function, such as treatment, prevention or alleviation of a patient's disease or disorder.

[0087] As used herein, the terms "effective amount", "pharmaceutically effective amount" and "therapeutically effective amount" refer to a non-toxic but sufficient amount of an agent or compound to provide a desired biological result. Such a result may be a reduction and / or alleviation of symptoms, signs or causes of a disease, or any other desired change in a biological system. One of ordinary skill in the art can determine the appropriate therapeutic amount in any individual case by routine experimentation.

[0088] As used herein, unless otherwise stated, the term "halo" or "halogen," by itself or as part of another substituent, refers to a fluorine, chlorine, bromine, or iodine atom, e.g., fluorine, chlorine, or bromine, e.g., fluorine or chlorine.

[0089] As used herein, unless otherwise indicated, the term "heteroalkyl" itself or in combination with another term refers to a stable straight or branched alkyl consisting of a specified number of carbon atoms and one or two heteroatoms selected from O, N and S, and wherein nitrogen atoms and sulphur atoms may be optionally oxidized, and nitrogen heteroatoms may be optionally quaternized. Heteroatoms (one or more) may be located at any position of heteroalkyl, such as between the remainder of heteroalkyl and the fragment connected thereto, and connected to the carbon atom at the farthest end in heteroalkyl. Examples include-O-CH-CH-CH,-CH-CH-CH-OH,-CH-CH-NH-CH,-CH-S-CH-CH and-CHCH-S (=O)-CH. Up to two heteroatoms may be continuous, such as, for example,-CHNH-OCH or-CHCH-SS-CH.

[0090] As used herein, unless otherwise indicated, the term "heterocycle" or "heterocyclyl" or "heterocyclic" by itself or as part of another substituent refers to an unsubstituted or substituted, stable monocyclic or polycyclic heterocyclic ring system consisting of carbon atoms and at least one heteroatom selected from N, O and S, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. Unless otherwise indicated, the heterocyclic ring system may be attached to any heteroatom or carbon atom that provides a stable structure. The heterocycle may be aromatic or non-aromatic in nature. In one embodiment, the heterocycle is a heteroaryl.

[0091] As used herein, the term "heteroaryl" or "heteroaromatic" refers to a heterocycle having aromatic characteristics. Polycyclic heteroaryl groups may include one or more partially saturated rings. Examples include tetrahydroquinoline and 2,3-dihydrobenzofuranyl.

[0092] Examples of non-aromatic heterocycles include monocyclic groups such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazoline, pyrazolidine, dioxolane, sulfolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, tetrahydrothiophane, piperidine, 1,2,3,6-tetrahydropyridine, 1,4-dihydropyridine, piperazine, morpholine, thiomorpholine, pyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane, homopiperazine, homopiperidine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethyleneoxide.

[0093] Examples of heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl (specifically 2- and 4-pyrimidinyl), pyridazinyl, thienyl, furanyl, pyrrolyl (specifically 2-pyrrolyl), imidazolyl, thiazolyl, oxazolyl, pyrazolyl (specifically 3- and 5-pyrazolyl), isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, tetrazolyl, 1,2,3-thiazolyl, 1,2,3-oxadiazolyl, 1,3,4-thiazolyl and 1,3,4-oxadiazolyl.

[0094] Examples of polycyclic heterocycles include indolyl (specifically 3-, 4-, 5-, 6- and 7-indolyl), dihydroindolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl (specifically 1- and 5-isoquinolyl), 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, quinoxalinyl (specifically 2- and 5-quinoxalinyl), quinazolinyl, phthalazinyl, 1,8-naphthyridinyl, 1,4-benzodioxanyl, coumarin, dihydrocoumarin, 1,5-naphthyridinyl, benzofuranyl (specifically 3-, 4-, 5-, 6- and 7-benzofuranyl), benzofuranyl, 2,3-dihydrobenzofuranyl, 1,2-benzoxazolyl, benzothiophenyl (specifically 3-, 4-, 5-, 6- and 7-benzothiophenyl), benzoxazolyl, benzothiazolyl (specifically 2-benzothiazolyl and 5-benzothiazolyl), purinyl, benzimidazolyl (specifically 2-benzimidazolyl), benzotriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrrolizidinyl and quinolizidinyl.

[0095] The listings of heterocyclyl and heteroaryl moieties provided herein are intended to be representative and not limiting.

[0096] As used herein, the term "substituted" refers to an atom or group of atoms that has replaced a hydrogen as a substituent attached to another group.

[0097] For cycloalkyl, aryl, heteroaryl and heterocycloalkyl, the term "substituted" as applied to the rings of these groups refers to any level of substitution where such substitution is permitted, i.e., mono-, di-, tri-, tetra- or penta-substitution. The substituents are independently selected, and substitution can be at any chemically accessible position. In certain embodiments, the number of substituents varies between 1 and 4. In other embodiments, the number of substituents varies between 1 and 3. In yet other embodiments, the number of substituents varies between 1 and 2.

[0098] In some embodiments, the substituents are each independently selected from -C1- C6 alkyl, -OH, -C 1- C6 alkoxy, halogen, -NH2, -N(CH3)2, -C(=O)OH, trifluoromethyl, -C≡N, -C(=O)O(C1-C4)alkyl, -C(=O)NH2, -NHC(=O)(aryl or alkyl), -SO2NH2, -C(=NH)NH2, -NO2, or any combination thereof. In some embodiments, the substituents are independently selected from C 1- C6 alkyl, C 1- C6 alkoxy, halo, acetamido and nitro. As used herein, when the substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic, wherein a straight chain is an illustrative example.

[0099] As used herein, the term "GT467" or "GTS467" refers to N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide or an enantiomer, salt or solvate thereof.

[0100] As used herein, the term "GT511" refers to N-(4-methoxyphenyl)-2-oxo-2-(4-phenylpiperazin-1-yl)acetamide or an enantiomer, salt or solvate thereof.

[0101] As used herein, the terms "patient," "subject," and "individual" refer interchangeably to a human or non-human mammal. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline, and murine mammals. For example, a patient or subject is a human.

[0102] As used herein, the term "pharmaceutical composition" refers to a mixture of at least one compound useful in the methods of the present invention and a pharmaceutically acceptable carrier. Pharmaceutical compositions facilitate administration of the compound to a patient. There are a variety of techniques for administering compounds in the art, including but not limited to intravenous, intramuscular, oral, aerosol, parenteral, intraocular, pulmonary, and topical administration.

[0103] As used herein, the term "pharmaceutically acceptable" refers to a relatively nontoxic material, such as a carrier or diluent, that does not abrogate the biological activity or properties of the compound, i.e., the material can be administered to an individual without causing adverse biological effects or interacting in a deleterious manner with any component of the composition in which it is contained.

[0104] As used herein, the term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or carrier that is involved in carrying or transporting a compound useful in the methods of the present invention in or to a patient so that it can perform its intended function, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent or encapsulating material. Typically, such a construct is carried or transported from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation (including the compounds useful in the methods of the present invention) and not harmful to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; surfactants; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic, compatible substances used in pharmaceutical formulations. As used herein, "pharmaceutically acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, etc. that are compatible with the activity of the compounds useful in the methods of the present invention and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the composition. "Pharmaceutically acceptable carrier" may further include pharmaceutically acceptable salts of compounds useful in the methods of the present invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the present invention are known in the art and are described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0105] As used herein, the term "prevent" or "prevention" means that if a disorder or disease has not yet occurred, it will not develop, or if a disorder or disease has already developed, the disorder or disease will not develop further. Also contemplated is the ability of one to prevent some or all of the symptoms associated with a disorder or disease.

[0106] The term "salt" includes addition salts of free acids or bases useful in the methods of the present invention. In certain embodiments, the salt is a pharmaceutically acceptable salt. The language "pharmaceutically acceptable salt" refers to a salt of an administered compound prepared from a pharmaceutically acceptable non-toxic acid or base including an inorganic acid or base, an organic acid or base, and a solvate, hydrate or clathrate thereof. However, pharmaceutically unacceptable salts may have properties such as high crystallinity, which have utility in the practice of the present invention, such as, for example, utility in the synthesis, purification or formulation of a compound useful in the methods of the present invention.

[0107] Suitable pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Examples of inorganic acids include sulfates, hydrogen sulfates, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid and phosphoric acid (including hydrogen phosphate and dihydrogen phosphate). Suitable organic acids may be selected from aliphatic, alicyclic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic acid classes of organic acids, examples of which include formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, 4-hydroxybenzoic acid, phenylacetic acid, mandelic acid, pamoic acid (or pamoic acid), methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, pantothenic acid, trifluoromethanesulfonic acid, 2-hydroxyethanesulfonic acid, p-toluenesulfonic acid, sulfanilic acid, cyclohexylaminosulfonic acid, stearic acid, alginic acid, β-hydroxybutyric acid, salicylic acid, galactaric acid and galacturonic acid.

[0108] Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include, for example, metal salts, including alkali metal, alkaline earth metal and transition metal salts, such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts prepared from basic amines such as, for example, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts can be prepared from the corresponding compounds, for example, by reacting a suitable acid or base with the compound.

[0109] As used herein, the term "treatment" or "treating" is defined as the application or administration of a therapeutic compound, i.e., a compound of the invention (alone or in combination with another therapeutic agent), to a patient, or the application or administration of a therapeutic compound to an isolated tissue or cell line from a patient suffering from a disease or disorder and / or symptoms of a disease or disorder (e.g., for diagnostic or ex vivo applications), with the purpose of treating, curing, alleviating, mitigating, altering, remedying, improving, enhancing, or affecting the disease or disorder and / or symptoms of a disease or disorder. Such treatment can be specifically tailored or modified based on knowledge gained from the field of pharmacogenomics.

[0110] Range: Throughout the disclosure, various aspects of the invention may be presented in a range format. It should be understood that the description in range format is for convenience and brevity only and should not be construed as a rigid limitation on the scope of the invention. Therefore, the description of a range should be considered to have explicitly disclosed all possible subranges and individual values ​​within the range. For example, a description of a range such as from 1 to 6 should be considered to have explicitly disclosed subranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual values ​​within the range, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

[0111] Compound

[0112] In one aspect, the invention relates to a compound. In some embodiments, the compound is a glutamate transport modulator, such as a GLT-1 modulator capable of modulating the activity of a GLT-1 protein. In some embodiments, the compound is a glutamate transport activator, such as a GLT-1 activator capable of increasing or upregulating the activity of a GLT-1 protein.

[0113] The compounds can be synthesized using techniques well known in the art of organic synthesis, such as those described in detail in the "Synthesis of Compounds" section below.

[0114] In some embodiments, the compound is of formula (I):

[0115]

[0116] or a salt, solvate, enantiomer, diastereomer, isotopically labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof,

[0117] Wherein in formula (I):

[0118] A is a key or where * is the bond to the carbonyl group;

[0119] R1-R 13 Each is independently selected from H, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 heteroalkyl and C3-C 10 Cycloalkyl, wherein alkyl, alkoxy, heteroalkyl and cycloalkyl are each independently optionally substituted, such as independently substituted with at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy;

[0120] R 14 is H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 10Cycloalkyl and phenyl, wherein alkyl, alkoxy, heteroalkyl and cycloalkyl are independently optionally substituted with at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy;

[0121] R 15 is phenyl optionally substituted by at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy.

[0122] In some embodiments, one or more of R1-R5 is C1-C6 alkoxy. In some embodiments, one or more of R1-R5 is C1-C6 alkoxy, and the remaining R1-R5 is H.

[0123] In some embodiments, R6-R 13 One or more of R6-R is H. In some embodiments, all R6-R 13 It's H.

[0124] In some embodiments, R 14 is optionally substituted phenyl.

[0125] In some embodiments, the compound is N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide (GT467) or N-(4-methoxyphenyl)-2-oxo-2-(4-phenylpiperazin-1-yl)acetamide (GT511), or a salt, solvate, enantiomer, diastereomer, isotope-labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof.

[0126] In some embodiments, the compound is (R)-N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide or (S)-N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide

[0127] The compounds of the present invention may have one or more stereocenters, and each stereocenter may exist independently in the (R) or (S) configuration. In certain embodiments, the compounds described herein exist in optically active or racemic forms. The compounds described herein include racemic, optically active, regioisomerism, and stereoisomeric forms or combinations thereof having therapeutically useful properties as described herein. The preparation of optically active forms is achieved in any suitable manner, including, as non-limiting examples, by resolution of the racemic form using recrystallization techniques, synthesis from optically active raw materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. The compounds described herein by racemic formula further represent two enantiomers or any mixture thereof, or, in the presence of two or more chiral centers, all diastereomers or any mixture thereof.

[0128] In certain embodiments, the compounds of the present invention exist as tautomers. All tautomers are included within the scope of the compounds described herein.

[0129] The compounds described herein also include isotopically labeled compounds in which one or more atoms are replaced by an atom having the same atomic number but an atomic mass or atomic mass number different from the atomic mass or atomic mass number usually found in nature. Examples of suitable isotopes for inclusion in the compounds described herein include, but are not limited to 2 H. 3 H. 11 C. 13 C. 14 C. 36 Cl, 18 F. 123 I. 125 I. 13 N. 15 N. 15 O. 17 O. 18 O. 32 P and 35 S. In certain embodiments, substitution with heavier isotopes such as deuterium provides greater chemical stability. Isotopically labeled compounds may be prepared by any suitable method or process using an appropriate isotopically labeled reagent in place of an otherwise unlabeled reagent.

[0130] In certain embodiments, the compounds described herein are labeled by other means, including but not limited to the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0131] In all embodiments provided herein, examples of suitable optional substituents are not intended to limit the scope of the claimed invention.The compounds of the present invention may contain any substituent or combination of substituents provided herein.

[0132] Salt

[0133] The compounds described herein may form salts with acids or bases, and such salts are included in the present invention. The term "salt" includes addition salts of free acids or bases useful in the methods of the present invention. The term "pharmaceutically acceptable salt" refers to salts having toxicity characteristics within a range useful in pharmaceutical applications. In certain embodiments, the salt is a pharmaceutically acceptable salt. However, pharmaceutically unacceptable salts may have properties such as high crystallinity, which have utility in the practice of the present invention, such as, for example, utility in the synthesis, purification or formulation of compounds useful in the methods of the present invention.

[0134] Suitable pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Examples of inorganic acids include sulfates, hydrogen sulfates, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid and phosphoric acid (including hydrogen phosphate and dihydrogen phosphate). Suitable organic acids may be selected from aliphatic, alicyclic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic acid classes of organic acids, examples of which include formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, 4-hydroxybenzoic acid, phenylacetic acid, mandelic acid, pamoic acid (or pamoic acid), methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, pantothenic acid, sulfanilic acid, 2-hydroxyethanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, cyclohexylaminosulfonic acid, stearic acid, alginic acid, β-hydroxybutyric acid, salicylic acid, galactaric acid, galacturonic acid, glycerophosphonic acid and saccharin (e.g., saccharinate, saccharate). A salt may consist of 1 molar equivalent, 1 or more than 1 molar equivalent of an acid or base relative to any compound of the invention.

[0135] Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include, for example, ammonium salts and metal salts, including alkali metal, alkaline earth metal and transition metal salts, such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts prepared from basic amines such as, for example, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (or N-methylglucamine) and procaine. All of these salts can be prepared from the corresponding compounds, for example, by reacting a suitable acid or base with the compound.

[0136] Synthesis of compounds

[0137] This specification further provides methods for preparing the compounds of this specification. The compounds of this specification can be prepared from commercially available starting materials, compounds known in the literature, or easily prepared intermediates using standard synthetic methods and procedures known to those skilled in the art, according to the procedures outlined herein. Standard synthetic methods and procedures for preparing organic molecules and functional group transformations and manipulations can be easily obtained from relevant scientific literature or standard textbooks in the field.

[0138] It should be understood that, unless otherwise stated, where typical or preferred process conditions (i.e., reaction temperatures, times, molar ratios of reactants, solvents, pressures, etc.) are given, other process conditions may also be used. Optimum reaction conditions may vary with the specific reactants or solvents used, but such conditions may be determined by those skilled in the art through routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented may be altered for the purpose of optimizing the formation of the compounds described herein.

[0139] The processes described herein can be monitored by any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatography, such as high performance liquid chromatography (HPLC), gas chromatography (GC), gel permeation chromatography (GPC), or thin layer chromatography (TLC).

[0140] The compounds described herein, as well as other related compounds with various substituents, were synthesized using the techniques and materials described herein and in the literature, e.g., Fieser & Fieser's Reagents for Organic Synthesis, Vols. 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Vols. 1-5 and Supplements (Elsevier Science Publishers, 1989); Organic Reactions, Vols. 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry, 4th Edition (Wiley 1992); Carey & Sundberg, Advanced Organic Chemistry, 4th Edition, Vols. A and B (Plenum 2000, 2001), and Green & Wuts, Protective Groups in Organic Synthesis, 3rd Edition, (Wiley 1999) (all of which disclosures are incorporated by reference). The general methods for preparing the compounds described herein can be modified by using appropriate reagents and conditions to introduce the various moieties found in the formulae described herein.

[0141] The compounds described herein are synthesized using any suitable procedure starting from compounds available from commercial sources, or are prepared using the procedures described herein.

[0142] In some embodiments, reactive functional groups, such as hydroxyl, amino, imino, sulfenyl or carboxyl, are protected to avoid them from undesirably participating in reactions. Blocking group is used to block some or all of the reactive moieties, and prevents such groups from participating in chemical reactions until blocking group is removed. In other embodiments, each blocking group can be removed in different ways. The blocking group of cracking under completely different reaction conditions meets the requirement of differential removal.

[0143] In certain embodiments, the protecting group is removed by acid, base, reducing conditions (such as, for example, hydrogenolysis), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal, and tert-butyldimethylsilyl are acid unstable and can be used to protect carboxyl and hydroxyl reactive moieties in the presence of amino groups protected by Cbz groups (which can be removed by hydrogenolysis) and Fmoc groups (which are base unstable). Carboxylic acid and hydroxyl reactive moieties can be blocked by base unstable groups (such as, but not limited to, methyl, ethyl, and acetyl) in the presence of amines, which are blocked by acid unstable groups (such as tert-butyl carbamate), or blocked by carbamates that are stable to both acid and base but can be removed by hydrolysis.

[0144] In some embodiments, carboxylic acid and hydroxyl reactive moieties are blocked by hydrolytically removable protecting groups (such as benzyl), while amine groups capable of acid hydrogen bonding are blocked by base labile groups (such as Fmoc). Carboxylic acid reactive moieties are protected by conversion to simple ester compounds exemplified herein, including conversion to alkyl esters, or blocked with oxidatively removable protecting groups such as 2,4-dimethoxybenzyl, while coexisting amino groups are blocked with fluorine-labile silyl carbamates.

[0145] Allyl blocking groups can be used in the presence of acid and base protecting groups, as the former are stable and will subsequently be removed by metal or pi-acid catalysts. For example, allyl blocked carboxylic acids can be deprotected by palladium catalyzed reactions in the presence of acid labile t-butyl carbamate or base labile acetamide protecting groups. Another form of protecting group is a resin to which the compound or intermediate is attached. As long as the residue is attached to the resin, the functional group is blocked and will not react. Once released from the resin, the functional group is available for reaction.

[0146] Typical blocking / protecting groups can be selected from:

[0147]

[0148] A detailed description of other protecting groups and techniques suitable for creating and removing protecting groups are described in Greene & Wuts, Protective Groups in Organic Synthesis, 3rd ed., John Wiley & Sons, New York, NY, 1999 and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference.

[0149] Composition

[0150] In some aspects, the invention relates to pharmaceutical compositions comprising the compounds contemplated herein.

[0151] In some embodiments, the composition is a composition for increasing GLT-1 activity. In some embodiments, the composition is useful for the methods contemplated herein.

[0152] In some embodiments, the composition is a composition that increases glutamate clearance by GLT-1 containing cells. In some embodiments, the composition is for use in the methods contemplated herein.

[0153] In some embodiments, the composition is a composition for preventing, treating and / or ameliorating a nervous system disorder. In some embodiments, the composition is useful for the methods contemplated herein.

[0154] Methods for increasing GLT-1 activity

[0155] In some aspects, the invention relates to a method of increasing the activity of GLT-1. In some embodiments, the method comprises contacting GLT-1 with a compound contemplated herein.

[0156] In some embodiments, GLT-1 is an isolated protein. In some embodiments, GLT-1 is on the surface of a cell. In some embodiments, GLT-1 is introduced into a cell by an exogenous source, such as expressed in a cell using an expression vector (such as a plasmid or a viral vector). In some embodiments, GLT-1 is endogenously expressed by a cell. In some embodiments, GLT-1 is on the surface of an astrocyte.

[0157] In some embodiments, GLT-1 is on the surface of astrocytes, wherein astrocytes are in the central nervous system (CNS) of a subject. In some embodiments, the subject is a mammal, such as a human. In some embodiments, the subject suffers from a disease that can benefit from the reduction of extracellular glutamate levels at the subject's synapses, and the method includes administering an effective amount of the compound to the subject. In some embodiments, the disease that benefits from the reduction of extracellular glutamate levels at the synapses is a nervous system disorder, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse behavior, and / or learning and memory impairment associated with the nervous system and neuropsychiatric diseases. In some embodiments, the compound is administered as a part of a pharmaceutical composition.

[0158] Methods for increasing glutamate clearance by GLT-1 containing cells

[0159] In some aspects, the invention relates to a method of increasing glutamate clearance by a cell, wherein the cell comprises GLT-1. In some embodiments, the method comprises contacting the cell with a compound contemplated herein.

[0160] In some embodiments, GLT-1 is introduced into cells exogenously, such as expressed in cells using an expression vector (e.g., a plasmid or viral vector). In some embodiments, GLT-1 is endogenously expressed by cells. In some embodiments, GLT-1 is on the surface of astrocytes.

[0161] In some embodiments, GLT-1 is on the surface of astrocytes, wherein astrocytes are in the central nervous system (CNS) of a subject. In some embodiments, the subject is a mammal, such as a human. In some embodiments, the subject suffers from a disease of glutamate clearance that can benefit from increase, such as glutamate clearance increased by astrocytes, and the method includes administering an effective amount of compound to the subject. In some embodiments, the disease that benefits from the increase in glutamate clearance is a nervous system disorder, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse behavior, and / or learning and memory impairment associated with nervous system and neuropsychiatric disorders. In some embodiments, the compound is a part of the pharmaceutical composition contemplated herein.

[0162] Methods for preventing, treating and / or ameliorating neurological disorders

[0163] In some aspects, the present invention relates to a method of preventing, treating and / or ameliorating a neurological disorder in a subject in need thereof. In some embodiments, the method comprises administering to the subject an effective amount of a compound contemplated herein.

[0164] In some embodiments, neurological disorders include Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse behaviors, and / or learning and memory impairments associated with nervous system and neuropsychiatric disorders.

[0165] In some embodiments, the nervous system disorder is Huntington's disease. In some embodiments, the method improves at least one of movement, learning and memory, and life expectancy in a patient suffering from Huntington's disease.

[0166] In some embodiments, the nervous system disorder is Parkinson's disease. In some embodiments, the method improves cognitive performance and / or reduces impulsivity in a patient with Parkinson's disease. In some embodiments, the method does not induce anxiety in a patient with Parkinson's disease.

[0167] In some embodiments, the compound is included in a pharmaceutical composition. In some embodiments, the pharmaceutical composition further includes one or more pharmaceutically acceptable carriers contemplated herein.

[0168] In some embodiments, the method further comprises administering an additional therapeutic agent to the subject. In some embodiments, the compound and the additional therapeutic agent are co-administered to the subject. In some embodiments, the compound and the additional therapeutic agent are co-formulated. In some embodiments, the compound is administered to the subject at a given time before or after administering the additional therapeutic agent to the subject.

[0169] In some embodiments, the subject is a mammal, such as a human.

[0170] Combination therapy

[0171] In a non-limiting embodiment, the compounds of the present invention are useful in the methods of the present invention in combination with one or more additional compounds for treating, improving and / or preventing the disease or disorder contemplated by the present invention or its complications or symptoms. These additional compounds may include compounds of the present invention or other compounds known to treat, prevent or alleviate the symptoms of the disease or disorder contemplated by the present invention, such as commercially available compounds.

[0172] In some embodiments, one or more additional compounds are administered prior to, after, or simultaneously with the administration of a compound of the invention.

[0173] In some non-limiting examples, additional compounds include dopamine agonists, such as rotigotine, carbidopa / levodopa, entacapone, ropinirole, cabergoline, pramipexole, tolcapone, bromocriptine or amantadine; antidepressants, such as rasagiline or selegiline; cognitive enhancement drugs, such as rivastigmine; anti-tremor drugs, such as benztropine; α-synuclein neutralizing antibodies, such as antibodies that neutralize α-synuclein oligomers or fibers; or other compounds that can be used to treat, prevent, improve and / or manage Parkinson's disease.

[0174] In some non-limiting examples, additional compounds include drugs that enhance cognition, such as memantine, rivastigmine, galantamine, donepezil; antibodies that are capable of removing amyloid plaques; or other compounds that can be used to treat, prevent, ameliorate and / or manage Alzheimer's disease.

[0175] In some non-limiting examples, the additional compound includes tetrabenazine, antipsychotic drugs, antidepressants, sedatives, or other compounds useful for treating, preventing, ameliorating, and / or managing Huntington's disease.

[0176] In non-limiting examples, additional compounds include glutamate blockers, such as riluzole (6-(trifluoromethoxy)benzothiazol-2-amine); muscle relaxants, such as baclofen or tizanidine; ceftriaxone ((6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)->2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid); or other compounds useful for treating, preventing, ameliorating and / or managing amyotrophic lateral sclerosis (ALS).

[0177] For example, a suitable method such as Sigmoid-E max The synergistic effect is calculated by the equation (Holford & Scheiner, 1981, Clin. Pharmacokinet. 6: 429-453), the Loewe additivity equation (Loewe & Muischnek, 1926, Arch. Exp. Pathol Pharmacol. 114: 313-326) and the median effect equation (Chou & Talalay, 1984, Adv. Enzyme Regul. 22: 27-55). Each of the equations mentioned above can be applied to experimental data to generate corresponding graphs to help evaluate the effect of drug combinations. The corresponding graphs associated with the equations mentioned above are concentration-effect curves, isobologram curves and combination index curves.

[0178] Drug combinations and preparations

[0179] This specification provides a pharmaceutical composition including at least one compound of this specification or its salt or solvate, which is used to practice the method of this specification. Such a pharmaceutical composition can be composed of at least one compound of this specification or salt or solvate suitable for application to a subject, or the pharmaceutical composition can include at least one compound of this specification or its salt or solvate and one or more pharmaceutically acceptable carriers, one or more other ingredients or any combination of these. As well known in the art, at least one compound of this specification can be in the form of a physiologically acceptable salt, such as being present in a pharmaceutical composition in combination with a physiologically acceptable cation or anion.

[0180] In some embodiments, the pharmaceutical composition for practicing the methods of the present specification can be administered to deliver a dose between 1 ng / kg / day and 100 mg / kg / day. In other embodiments, the pharmaceutical composition for practicing the present specification can be administered to deliver a dose between 1 ng / kg / day and 1,000 mg / kg / day.

[0181] The relative amounts of the active ingredient, pharmaceutically acceptable carrier, and any additional ingredients in the pharmaceutical compositions of the present specification will vary, depending on the identity, size, and condition of the subject being treated, and further on the route by which the composition is administered. For example, the composition may include between 0.1% and 100% (w / w) of the active ingredient.

[0182] The pharmaceutical composition used in the method of the present specification can be appropriately developed for nasal, inhalation, oral, rectal, vaginal, pleural, peritoneal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, intraocular, epidural, intrathecal, intravenous or another route of administration. The composition used in the method of the present specification can be directly administered to the brain, brain stem or any other part of the central nervous system of a mammal or bird. Other preparations considered include designed (project) nanoparticles, microspheres, liposome preparations, coated particles, polymer conjugates, resealed erythrocytes containing active ingredients, and immunologically based preparations.

[0183] In some embodiments, the composition of this specification is a part of a drug matrix, which allows the processing of insoluble materials and improves its bioavailability, the development of controlled release or sustained release products, and the production of homogeneous compositions. For example, hot melt extrusion, solid solutions, solid dispersions, size reduction techniques, molecular complexes (e.g., cyclodextrins, etc.), microparticles, and granules and formulation coating methods can be used to prepare drug matrices. Amorphous or crystalline phases can be used in this process.

[0184] The route(s) of administration will be apparent to the skilled artisan and will depend on a number of factors including the type and severity of the disease being treated, the type and age of the veterinary or human patient being treated, and the like.

[0185] The preparation of the pharmaceutical composition described herein can be prepared by any method known or later developed in the field of pharmacology and pharmaceutics. Generally, such preparation methods include the steps of combining the active ingredient with a carrier or one or more other auxiliary ingredients, and then, if necessary or desired, shaping or packaging the product into a desired single or multiple dose unit.

[0186] As used herein, a "unit dose" is a pharmaceutical composition comprising a discrete amount of a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient to be administered to the subject or a convenient portion of such a dosage, such as, for example, half or one-third of such a dosage. The unit dosage form can be a single daily dose or one of multiple daily doses (e.g., about 1-4 times or more per day). When multiple daily doses are used, the unit dosage form for each administration can be the same or different.

[0187] Although the description of the pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions suitable for ethical administration to humans, it will be appreciated by the skilled artisan that such compositions are generally suitable for administration to various animals. In order to make the compositions suitable for administration to various animals, improvements to pharmaceutical compositions suitable for administration to humans are well known, and veterinary pharmacists of ordinary skill can design and perform such improvements only through ordinary experiments. It is contemplated that subjects to whom the pharmaceutical compositions of this specification are administered include, but are not limited to, humans and other primates, mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.

[0188] In some embodiments, the compositions of the present specification are formulated using one or more pharmaceutically acceptable excipients or carriers. In some embodiments, the pharmaceutical compositions of the present specification include a therapeutically effective amount of at least one compound of the present specification and a pharmaceutically acceptable carrier. Useful pharmaceutically acceptable carriers include, but are not limited to, glycerol, water, saline, ethanol, recombinant human albumin (e.g., ), soluble gels (e.g., ) and other pharmaceutically acceptable salt solutions, such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).

[0189] The carrier can be a solvent or dispersion medium, which comprises, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.), recombinant human albumin, soluble gelatin, suitable mixtures thereof and vegetable oils. For example, a coating such as lecithin can be used, by maintaining the required particle size in the presence of a dispersion and by using a surfactant to maintain suitable fluidity. The effect of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, isotonic agents are included in the composition, such as sugar, sodium chloride or polyols, such as mannitol and sorbitol. The extended absorption of the injectable composition can be achieved by including an agent such as aluminum monostearate or gelatin that delays absorption in the composition.

[0190] Preparation can be used in combination with conventional excipients, i.e. suitable for oral, parenteral, nasal, inhaled, intravenous, subcutaneous, percutaneous enteral or any other suitable mode of administration known in the art. Pharmaceutical preparations can be sterilized, and if necessary, can be mixed with adjuvants such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for affecting osmotic pressure buffers, coloring agents, flavoring agents and / or materials that impart fragrance, etc. When necessary, they can also be combined with other activating agents, such as other analgesics, antianxiety agents or hypnotic agents. As used herein, "other composition" includes but is not limited to one or more compositions that can be used as a pharmaceutical carrier.

[0191] The compositions of this specification may include about 0.005% to 2.0% preservatives by the total weight of the composition. Preservatives are used to prevent deterioration in the case of exposure to pollutants in the environment. Examples of useful preservatives according to this specification include, but are not limited to, those selected from benzyl alcohol, sorbic acid, p-hydroxybenzoic acid, imidourea, and any combination thereof. One such preservative is a combination of about 0.5% to 2.0% benzyl alcohol and 0.05-0.5% sorbic acid.

[0192] The composition can include antioxidants and chelating agents that inhibit compound degradation. For some compounds, the antioxidant is BHT, BHA, alpha-tocopherol and ascorbic acid, and its exemplary range is about 0.01% to 0.3% by weight, or BHT range is 0.03% to 0.1% by weight by the total weight of the composition. By the total weight of the composition, the amount of chelating agent present can be 0.01% to 0.5% by weight. By the total weight of the composition, exemplary chelating agents include ethylenediaminetetraacetic acid salts (e.g., disodium ethylenediaminetetraacetic acid) and citric acid in the range of about 0.01% to 0.20% by weight or in the range of 0.02% to 0.10% by weight. Chelating agents can be used to chelate metal ions in the composition, which may be harmful to the shelf life of the preparation. For some compounds, although BHT and disodium ethylenediaminetetraacetic acid are exemplary antioxidants and chelating agents, respectively, as known to those skilled in the art, other suitable and equivalent antioxidants and chelating agents can be substituted.

[0193] Conventional methods can be used to prepare liquid suspensions so that the active ingredient is suspended in an aqueous or oily vehicle. Aqueous vehicles include, for example, water and isotonic saline. Oily vehicles include, for example, almond oil, oily esters, ethanol, vegetable oils such as peanut oil, olive oil, sesame oil or coconut oil, fractionated vegetable oils and mineral oils such as liquid paraffin. Liquid suspensions may further include one or more other ingredients, including but not limited to suspending agents, dispersants or wetting agents, emulsifiers, mitigating agents, preservatives, buffers, salts, flavoring agents, coloring agents and sweeteners. Oily suspensions may further include thickeners. Known suspending agents include but are not limited to sorbitol syrups, hydrogenated edible fats, sodium alginate, polyvinyl pyrrolidone, tragacanth gum, gum arabic and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose. Known dispersants or wetting agents include but are not limited to naturally occurring phosphatides such as lecithin, condensation products of alkylene oxides and fatty acids, long-chain aliphatic alcohols, partial esters derived from fatty acids and hexitol or partial esters derived from fatty acids and hexitol anhydrides (for example, polyoxyethylene stearate, 17 carbon ethyleneoxy cetyl alcohol, polyoxyethylene sorbitol monooleate and polyoxyethylene sorbitan monooleate, respectively). Known emulsifiers include but are not limited to lecithin, gum arabic and ionic or nonionic surfactants. Known preservatives include but are not limited to methyl parahydroxybenzoate, ethyl parahydroxybenzoate or n-propyl parahydroxybenzoate, ascorbic acid and sorbic acid. Known sweeteners include, for example, glycerol, propylene glycol, sorbitol, sucrose and saccharin.

[0194] The liquid solution of active ingredient in aqueous or oily solvent can be prepared in the same manner as liquid suspension, and the main difference is that active ingredient is dissolved rather than suspended in solvent. As used herein, "oiliness" liquid is a liquid that includes carbon-containing liquid molecules and exhibits polarity less than water. The liquid solution of the pharmaceutical composition of this specification sheet can include every kind of component described about liquid suspension, and it should be understood that suspending agent will not necessarily help active ingredient to be dissolved in solvent. Aqueous solvents include, for example, water and isotonic saline. Oily solvents include, for example, almond oil, oily esters, ethanol, vegetable oils such as peanut oil, olive oil, sesame oil or coconut oil, fractionated vegetable oils and mineral oils such as liquid paraffin.

[0195] The powdered and granular preparations of the pharmaceutical preparations of this specification sheet can be prepared using known methods. Such preparations can be directly applied to the subject, for example, for forming tablets, filling capsules, or preparing aqueous or oily suspensions or solutions by adding aqueous or oily vehicles thereto. Each of these preparations can further include one or more of a dispersant or wetting agent, a suspending agent, an ionic and nonionic surfactant, and a preservative. Other excipients can also be included in these preparations, such as fillers and sweeteners, flavoring agents, or coloring agents.

[0196] The pharmaceutical composition of this specification can also be prepared, packaged or sold in the form of an oil-in-water emulsion or an oil-in-water emulsion. The oil phase can be a vegetable oil such as olive oil or peanut oil, a mineral oil such as liquid paraffin, or a combination of these. Such a composition can further include one or more emulsifiers, such as naturally occurring gums such as gum arabic or gum tragacanth; naturally occurring phospholipids, such as soybeans or lecithin; esters or partial esters derived from a combination of fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of this partial ester with ethylene oxide, such as polyoxyethylene sorbitan monooleate. These emulsions can also include additional ingredients, including, for example, sweeteners or flavorings.

[0197] Methods for impregnating or coating materials with chemical compositions are known in the art and include, but are not limited to, methods for depositing or binding chemical compositions onto surfaces, methods for incorporating chemical compositions into material structures during synthesis of materials (i.e., such as using physiologically degradable materials), and methods for absorbing aqueous or oily solutions or suspensions into absorbent materials, with or without subsequent drying. Methods for mixing components include physical grinding, use of pellets in solid and suspension formulations, and mixing in transdermal patches, as known to those skilled in the art.

[0198] Administration / dosage / formulation

[0199] The dosing regimen may affect what constitutes an effective amount. The therapeutic formulation may be administered to the patient before or after the onset of the disease or disorder. In addition, several separate doses and staggered doses may be administered daily or sequentially, or the dose may be infused continuously, or may be a bolus injection. In addition, the dose of the therapeutic formulation may be increased or decreased in proportion to the urgency of the treatment or prevention situation.

[0200] The compositions of the present invention can be administered to a patient, such as a mammal, such as a human, using known procedures, in a dosage and time period that is effective for treating a disease or disorder in the patient. The effective amount of the therapeutic compound necessary to achieve the therapeutic effect can vary according to factors such as the state of the patient's disease or disorder, the patient's age, sex and weight, and the ability of the therapeutic compound to treat the patient's disease or disorder. The dosage regimen can be adjusted to provide the best therapeutic response. For example, as indicated by the emergency of the treatment situation, several separate doses can be administered daily or the dosage can be proportionally reduced. A non-limiting example of the effective dose range of the therapeutic compound of the present invention is about 1 to 5,000 mg / kg body weight per day. One of ordinary skill in the art will be able to study the relevant factors and determine the effective amount of the therapeutic compound without excessive experimentation.

[0201] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0202] In particular, the selected dosage level will depend upon a variety of factors, including the activity of the particular compound employed, the time of administration, the excretion rate of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and similar factors well known in the medical arts.

[0203] A physician, such as a physician or veterinarian, having ordinary skills in the art can easily determine and prescribe the desired effective amount of the pharmaceutical composition. For example, a physician or veterinarian can start the dosage of the compound of the present invention used in the pharmaceutical composition at a level lower than that required in order to obtain the desired therapeutic effect and gradually increase the dosage until the desired effect is obtained.

[0204] In a specific embodiment, formulating the compound in dosage unit form is particularly advantageous for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patient to be treated; each unit contains a predetermined quantity of the therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle.

[0205] In certain embodiments, the compositions of the present invention are formulated using one or more pharmaceutically acceptable excipients or carriers. In certain embodiments, the pharmaceutical compositions of the present invention include a therapeutically effective amount of a compound of the present invention and a pharmaceutically acceptable carrier.

[0206] The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.

[0207] In certain embodiments, the compositions of the present invention are administered to the patient with a dosage in the range of 1-5 times or more per day. In other embodiments, the compositions of the present invention are administered to the patient with a dosage range including but not limited to once a day, once every two days, once every three days to once a week and once every two weeks. It is apparent to those skilled in the art that the frequency of administration of the various combination compositions of the present invention will vary from individual to individual, depending on many factors, including but not limited to age, disease to be treated or disorder, sex, overall health and other factors. Therefore, the present invention should not be construed as being limited to any specific dosage regimen, and will be determined by the attending physician taking into account all other factors of the patient to determine the precise dosage and composition to be administered to any patient.

[0208] The compounds of the invention for administration may range from about 1 μg to about 10,000 mg, about 20 μg to about 9,500 mg, about 40 μg to about 9,000 mg, about 75 μg to about 8,500 mg, about 150 μg to about 7,500 mg, about 200 μg to about 7,000 mg, about 3050 μg to about 6,000 mg, about 500 μg to about 5,000 mg, about 750 μg to about 4,000 mg, From about 1 mg to about 3,000 mg, from about 10 mg to about 2,500 mg, from about 20 mg to about 2,000 mg, from about 25 mg to about 1,500 mg, from about 50 mg to about 1,000 mg, from about 75 mg to about 900 mg, from about 100 mg to about 800 mg, from about 250 mg to about 750 mg, from about 300 mg to about 600 mg, from about 400 mg to about 500 mg, and any whole and partial increments therebetween.

[0209] In some embodiments, the dose of the compound of the invention is from about 1 mg to about 2,500 mg. In some embodiments, the dose of the compound of the invention used in the compositions described herein is less than about 10,000 mg, or less than about 8,000 mg, or less than about 6,000 mg, or less than about 5,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some embodiments, the dose of the second compound described herein (i.e., the drug for treating a disease or disorder, or a complication or symptom thereof) is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any full or partial increments thereof.

[0210] In certain embodiments, the invention relates to packaged pharmaceutical compositions comprising a container holding a therapeutically effective amount of a compound of the invention, alone or in combination with a second drug; and instructions for using the compound to treat, prevent, or ameliorate one or more symptoms of a disease or disorder in a patient.

[0211] The preparations can be mixed with conventional excipients (i.e., pharmaceutically acceptable organic or inorganic carrier materials suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral or any other suitable administration known in the art). The pharmaceutical preparations can be sterilized and, if necessary, can also be mixed with adjuvants such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts of buffers that affect osmotic pressure, colorants, flavorings and / or aromatic substances. They can also be used in combination with other active agents (e.g., other analgesics) as needed.

[0212] The administration routes of any composition of the present invention include nasal, inhalation, topical, oral, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intratracheal, intraauricular, intraocular, intrathecal and intravenous. The compounds used in the present invention can be formulated for administration by any suitable route, such as oral or parenteral, such as transdermal, transmucosal (e.g., sublingual, lingual, buccal, urethral, ​​vaginal (e.g., vaginal and perivaginal), nasal (intra) and (rectal), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, subcutaneous, intramuscular, intradermal, intraarterial, intravenous, intrabronchial, inhalation and topical administration.

[0213] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, soft gelatin capsules, lozenges, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration, etc. It should be understood that the formulations and compositions useful in the present invention are not limited to the specific formulations and compositions described herein.

[0214] Oral administration

[0215] For oral administration, tablets, lozenges, liquids, drops, suppositories or capsules, caplets and soft capsules are particularly suitable. Compositions intended for oral use can be prepared according to any method known in the art, and such compositions can contain one or more agents selected from inert, non-toxic, pharmaceutical excipients suitable for making tablets. Such excipients include, for example, inert diluents such as lactose; granulating agents and disintegrants, such as corn starch; binders, such as starch; and lubricants, such as magnesium stearate. Tablets may be uncoated or may be coated by known techniques for elegance or delayed release of the active ingredient. Oral preparations may also be present in hard gelatin capsules, in which the active ingredient is mixed with an inert diluent.

[0216] For oral administration, the compounds of the present invention can be in the form of tablets or capsules prepared by conventional methods with pharmaceutically acceptable excipients such as binders (e.g., polyvinyl pyrrolidone, hydroxypropyl cellulose or methyl cellulose, hydroxypropyl methyl cellulose); fillers (e.g., corn starch, lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silicon dioxide); disintegrants (e.g., sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). If necessary, suitable methods and coating materials such as those available from Colorcon, West Point, Pa. (e.g., OPADRY TM OY, OYC, organic enteric-coated OY-P, aqueous enteric-coated OY-A, OY-PM and OPADRY TM OPADRY (White, 32K18400) TM The film coating system coats the tablet. Liquid preparations for oral administration may be in the form of solutions, syrups or suspensions. Liquid preparations may be prepared in a conventional manner with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methylcellulose or hydrogenated edible fats); emulsifiers (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethanol); and preservatives (e.g., methyl or propyl paraben or sorbic acid).

[0217] The present invention also includes multilayer tablets comprising a layer for delayed release of one or more compounds of the present invention and another layer for immediate release of a drug for treating a disease or disorder. Using wax / pH sensitive polymer mixtures, gastro-insoluble compositions can be obtained in which the active ingredient is entrapped, thereby ensuring its delayed release.

[0218] Parenteral administration

[0219] For parenteral administration, the compounds of the invention can be formulated for injection or infusion, e.g., intravenous, intramuscular or subcutaneous injection or infusion, or administered as a single dose and / or continuous infusion. Suspensions, solutions or emulsions in oily or aqueous vehicles can be used, optionally containing other preparations, such as suspending agents, stabilizers and / or dispersants.

[0220] Other forms of administration

[0221] Additional dosage forms of the present invention include dosage forms as described in U.S. Patent Nos. 6,340,475, 6,488,962, 6,451,808, 5,972,389, 5,582,837 and 5,007,790. Additional dosage forms of the present invention also include dosage forms as described in U.S. Patent Application Nos. 20030147952, 20030104062, 20030104053, 20030044466, 20030039688 and 20020051820. Additional dosage forms of the present invention also include dosage forms as described in PCT Application Nos. WO 03 / 35041, WO 03 / 35040, WO 03 / 35029, WO 03 / 35177, WO 03 / 35039, WO 02 / 96404, WO 02 / 32416, WO 01 / 97783, WO 01 / 56544, WO 01 / 32217, WO 98 / 55107, WO 98 / 11879, WO 97 / 47285, WO 93 / 18755 and WO 90 / 11757.

[0222] Controlled release formulations and drug delivery systems

[0223] In certain embodiments, the formulations of the present invention may be, but are not limited to, short-term, rapid-release, and controlled release such as sustained-release, delayed-release, and pulsed-release formulations.

[0224] The term sustained release in its conventional sense refers to a pharmaceutical formulation that releases a drug gradually over an extended period of time, although not necessarily, resulting in substantially constant blood levels of the drug over the extended period of time. This period of time may be as long as a month or more, and should be longer than the release of the same amount administered as a bolus injection.

[0225] For sustained release, the compound can be formulated with a suitable polymer or hydrophobic material that provides the compound with sustained release properties. Like this, the compound used in the method of the invention can be administered in microparticle form, for example by injection, or in wafer or disc form, by implantation.

[0226] In a specific embodiment of the invention, a sustained release formulation is used to administer the compounds of the invention alone or in combination with another pharmaceutical agent to a patient.

[0227] The term delayed release is used herein in its conventional sense to refer to drug formulations that provide initial release of the drug after a certain delay after drug administration, and although not necessarily, may include from about 10 minutes up to about 12 hours.

[0228] The term pulsatile release is used herein in its conventional sense to refer to drug formulations that provide for release of the drug in a manner that produces a pulsatile plasma profile following drug administration.

[0229] The term immediate release in its conventional sense refers to a pharmaceutical formulation that provides for release of the drug immediately after administration of the drug.

[0230] As used herein, short-term refers to any time period following drug administration, up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes following drug administration and any or all full or partial increments thereof.

[0231] As used herein, rapid compensation refers to any time period after drug administration, up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes or about 10 minutes, and any full and partial increments thereof.

[0232] Drug administration

[0233] The therapeutically effective amount or dosage of the compounds of the present invention will depend on the age, sex and weight of the patient, the patient's current medical condition and the progression of the disease or disorder being treated in the patient. The skilled person will be able to determine the appropriate dosage based on these and other factors.

[0234] The suitable dosage of the compound of the present invention can be in the range of about 0.01 mg to about 5,000 mg per day, such as about 0.1 mg to about 1,000 mg per day, such as about 1 mg to about 500 mg, such as about 5 mg to about 250 mg per day. Administration can be a single dose or multiple doses, such as 1 to 4 times or more per day. When multiple doses are used, the amount of each dose can be the same or different. For example, a dose of 1 mg per day can be administered as two doses of 0.5 mg, each administration being about 12 hours apart.

[0235] It is understood that, in non-limiting examples, the amount of compound administered daily may be once every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, when administered every other day, a daily dose of 5 mg may be initiated on Monday, followed by a first daily dose of 5 mg on Wednesday, followed by a second daily dose of 5 mg on Friday, and so on.

[0236] The compounds used in the methods of the present invention can be formulated in unit dosage form. The term "unit dosage form" refers to a physically discrete unit suitable as a unit dosage for a patient receiving treatment, each unit containing a predetermined amount of active substance calculated to produce a desired therapeutic effect, optionally combined with a suitable pharmaceutical carrier. The unit dosage form can be used for a single daily dose or multiple daily doses (e.g., about 1 to 4 times or more per day). When multiple doses are used per day, the unit dosage form of each dose can be the same or different.

[0237] Using only routine experiments, those skilled in the art will recognize or be able to determine many equivalents of the specific procedures, embodiments, claims and embodiments described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the appended claims. For example, it should be understood that improvements in the reaction conditions including but not limited to reaction time, reaction size / volume and experimental reagents such as solvents, catalysts, pressures, atmospheric conditions such as nitrogen atmosphere and reducing agent / oxidant using art-recognized alternatives and using only routine experiments are within the scope of the present application.

[0238] It should be understood that no matter where numerical values ​​and ranges are provided herein, all values ​​and ranges contained in these values ​​and ranges are intended to be contained within the scope of the present invention. In addition, this application also contemplates all values ​​falling within these ranges and the upper or lower limit of the range of this value.

[0239] The following examples further illustrate aspects of the present invention. However, they are in no way limiting to the teachings or disclosures of the present invention described herein.

[0240] Example

[0241] This specification is further described in detail with reference to the following experimental examples. These examples are provided for illustrative purposes only and are not intended to be limiting unless otherwise stated. Therefore, this specification should never be interpreted as being limited to the following examples, but should be interpreted as including any and all changes shown by the teachings provided herein.

[0242] Example 1-1:

[0243] Glutamate is a major excitatory neurotransmitter in the central nervous system that plays a key role in neuroplasticity, cognition, learning, memory, and development. Glutamate neurotransmission is tightly regulated by a network of metaboreceptors, ionotropic receptors, and transporters distributed on neurons, glia, and other cell types in the brain. Under healthy conditions, depolarization of glutamatergic neurons results in the release of glutamate from presynaptic vesicles in a calcium-dependent manner, which then activates postsynaptic ionotropic NMDA and AMPA receptors, which facilitate activation of a calcium-dependent signaling cascade in the postsynaptic neuron. Excess glutamate is rapidly cleared from the synapse by the glutamate reuptake transporters of astrocytes, which are involved in the mitochondria-3-hydroxylation of glutamate and 3-Na. + Co-transport and K + Active transport of antiport of ions. Clearing excess glutamate from synapses prevents overstimulation of postsynaptic and extrasynaptic NMDA receptors to prevent excitotoxicity. In perisynaptic astrocytes, glutamate is converted to glutamine by glutamine synthetase, and glutamine is recycled into neurons where it is converted back to glutamate by glutaminase and then packaged into vesicles by the vesicular glutamate transporter.

[0244] Glutamate transporters are divided into five subtypes in rodents and humans. The three rodent transporters are called GLAST, GLT1, and EAAC1, which are mainly transported in the rat brain. The human homologs of these three transporters are called excitatory amino acid transporters (EAATs) EAAT1, EAAT2, and EAAT3, respectively. The remaining two, EAAT4 and EAAT5, are named the same in rodents and humans. These transporters are expressed differently in different brain regions; GLAST is more prominent in the cerebellum, GLT1 (or EAAT2) is mainly found in the forebrain, and expression in the cerebellum is very low. They are found on the membranes of astrocytes or in Bregman glial cells associated with excitatory synapses. EAAT3 is ubiquitous in various brain regions. EAAT4 and EAAT5 are expressed in the cerebellum and retina, respectively. EAAT2 is the most common subtype and accounts for 85-90% of the terminal glutamate reuptake. Dysfunction or downregulation of EAAT2 results in excessive accumulation of glutamate, which not only overactivates postsynaptic NMDA and AMPA receptors, but also activates extrasynaptic NMDA receptors, leading to calcium-mediated excitotoxicity and death. This form of excitotoxicity has been implicated in a variety of neurological disorders, including ALS, AD, HD, and PD, and dysfunction of EAAT2 has been documented in these disorders, suggesting that EAAT2 may be a novel drug target for the treatment of excitotoxicity in these diseases. In fact, the β-lactam antibiotic ceftriaxone, which functions as a nonspecific EAAT2 activator, has passed Phase 3 clinical trials for the treatment of ALS. To develop novel EAAT2 activators, a cell-based enzyme-linked immunosorbent assay (ELISA) was developed in which a primary astrocyte cell line was stably transfected with a designed EAAT2 regulatory vector. This assay was used for high-throughput screening of a glutamate reuptake compound library using the MDCK-hEAAT2 transflex plate assay. Several hits with micromolar potency in the glutamate reuptake assay were identified using this method. A small molecule activator of EAAT2 was designed and tested for efficacy in preclinical models of ALS and epilepsy. However, none of these molecules became FDA-approved drugs due to off-target toxicity or lack of translatable physicochemical properties.

[0245] A series of EAAT2 small molecule activators such as GT951 were developed using a structure-based hybrid screening approach (see WO 2018 / 132829A1, the entire contents of this PCT publication are incorporated herein by reference). GT951 and its analogs are highly selective and specific for EAAT2, have nanomolar efficacy, and do not activate postsynaptic NMDA receptors. Site-directed mutagenesis studies have confirmed that these compounds bind to an isomeric site that is located at the interface between the trimerization domain and the transport domain, but close to the substrate binding domain. In this study, the pharmacokinetic characteristics of the compound GT951 were determined, and structure-guided medicinal chemistry optimization was performed to obtain the new molecules GT467 and GT511, and their pharmacokinetic characteristics were tested in rats.

[0246] Examples 1-2: Materials and Methods

[0247] Library design and molecular docking

[0248] The three-dimensional structure of EAAT2 was modeled using bacterial GltPh. The binding pocket of GT951 and its analogs was validated using site-directed mutagenesis studies and showed that the binding site is distinct from the substrate transport domain. Using the pharmacological structure derived from GT951, a small molecule library was screened using a structure-based hybrid screening approach to obtain 3822 hit molecules. These molecules were docked to the same binding pocket using GOLD docking software and scored using GoldScore. The 10 best-ranked molecules were synthesized from the ranked molecules and tested for glutamate uptake using an in vitro transflex plate assay.

[0249] Chemicals and reagents

[0250] Common reagents and solvents are purchased from commercial suppliers, and unless otherwise specified, no further purification is required. Compounds (D1-D9) are generously provided by EDASA Scientific. Tetrahydrofuran (THF) is distilled from sodium benzophenone under argon. The reaction progress is monitored using analytical thin layer chromatography (TLC) on pre-coated silica gel GF254 flat plates (Macherey Nagel GmbH & Co. KG, Düren, Germany), and spots are detected under ultraviolet light (254 and 366nm). Compounds are purified using flash column chromatography, using silica gel (Merck, Darmstadt, Germany) with a particle size of 40-63 μM as stationary phase, and hexane / ethyl acetate or dichloromethane / methanol mixtures as elution systems. Nuclear magnetic resonance spectra are measured in deuterated solvents (DMSO-d6, CDCl3, MeOD-d4) by Bruker AV-400NMR instruments (Bruker, Karlsruhe, Germany). Chemical shifts are expressed in ppm relative to DMSO-d6, CDCl3 or MeOD-d4 (2.50 / 7.26 / 3.31 for 1H; 39.52 / 77.16 / 49.00 for 13C). The following abbreviations are used to set the multiples: s = single, d = double, t = triple, q = quadruple, m = multiple, br. = broad. IR spectra were recorded in KBr by Thermo Nicolet IR-200. Mass spectra were recorded by Finnigan MAT mass spectrometer using electron impact ionization (direct inlet) and ITD-700 detector. The ionization electron energy was 70 eV and the mass range was m / z 35-400. Verification and purity measurements of the compounds were performed by LC / MS. LC-MS / MS data were obtained using a Dionex Ultimate 3000 liquid chromatograph (Dionex, USA) connected to an AB Sciex Qtrap 3200 mass spectrometer (AB Sciex, Canada). LC separations were performed on a Shim-pack GIST C18-AQ (150 mm × 2.1 mm, 3 μm, Shimadzu, Japan) column. The mobile phase consisted of a mixture of 10 mM ammonium formate in water (A) and acetonitrile (B) solution to which 0.2% (v / v) formic acid had been added. The following gradient program was applied: 0.0-1.0 min (5% B), 1.0-7.5 min (5% B-50% B), 7.5-8.5 min (50% B-90% B), 8.5-11.5 min (90% B-90% B), 11.5-12.0 min (90% B-5% B), 12.0-17.0 min (5% B-5% B). The mobile phase flow rate was 0.4 mL min -1The injection volume was 10 μL. Compounds were detected at λ=254 nm and the purity of the target compounds was ≥95%. High resolution mass spectrometry (HRMS) was measured on a Bruker maX instrument using electrospray ionization (ESI) technique. Melting points were measured in open capillaries and are presented without correction. All reactions were performed on a gram scale.

[0251] Synthesis and characterization of compounds

[0252]

[0253] Ethyl 2-((4-methoxyphenyl)amino)-2-oxoacetate (2)

[0254] 4-Methoxyaniline (1) (20 g, 162 mmol, 1 equiv.) was added to a solution of diethyl oxalate (88 mL, 649 mmol, 4 equiv.) at ambient temperature. The reaction mixture was stirred at 150°C for 4 hours. After the reaction was confirmed to be complete by TLC analysis, the resulting solution was cooled to room temperature and poured into 250 mL of hexane. The white precipitate was collected by filtration and dried to obtain 30 g of a light yellow solid. (Yield: 83%), melting point = 99°C (literature melting point (lit.mp) = 100-104°C)

[0255] 1 H NMR (400MHz, CDCl3): δ=8.83 (br. S., 1H), 7.59 (d, J=9.2Hz, 2H), 6.92 (d, J=8.9Hz, 2H), 4.43 (q, J=7.3Hz, 2H), 3.83 (s, 3H), 1.44 (t, J=7.2Hz, 3H).

[0256] 2-((4-Methoxyphenyl)amino)-2-oxoacetic acid (3)

[0257] Ethyl 2-((4-methoxyphenyl)amino)-2-oxoacetate (2) (11.15 g, 50 mmol, 1 equiv.) was dissolved in MeOH-THF-H2O (25+25+25 ml) system, and then LiOH*H2O (2.25 g, 55 mmol, 1.1 equiv.) was added in one portion. The reaction mixture was stirred at room temperature for 1 hour, then THF and MeOH were evaporated, and the aqueous phase was acidified with 10% HCl until pH = 1. The precipitate was filtered off and dried in vacuo to obtain 8.3 g (85%) of 3 as a white solid of analytical purity, melting point = 206°C (decomposition) (literature melting point = 215°C (decomposition)).

[0258] 1H NMR (400MHz, DMSO-d6): δ=14.10 (br. S., 1H), 10.61 (s, 1H), 7.68 (d, J=8.9Hz, 2H), 6.92 (d, J=8.9Hz, 2H), 3.73 (s, 3H).

[0259]

[0260] tert-Butyl 4-phenylpiperazine-1-carboxylate (5)

[0261] A suspension of BINAP (7.5 g, 12.2 mmol, 0.1 equiv) in 125 ml of dry toluene was heated to reflux and cooled to 80°C. Palladium acetate (1.37 g, 6.1 mmol, 0.05 equiv) was then added under argon and the resulting solution was left to cool to room temperature. Amine (4) (22.78 g, 122 mmol, 1 equiv), bromobenzene (12.76 ml, 122 mmol, 1.2 equiv) and cesium carbonate (80 g, 244 mmol, 2 equiv) were then added. The resulting suspension was heated at 80°C for 20 hours before all the starting amine was converted. After completion of the reaction, the solvent was evaporated under vacuum and the resulting mixture was separated by flash chromatography using a mixture of hexane-ethyl acetate (3:1, Rf=0.4) as the eluent to afford 20.8 g (65%) of (5) as a white solid of analytical purity, melting point = 95-97°C (literature melting point = 100-104°C).

[0262] 1 H NMR (400MHz, CDCl3): δ=7.27-7.32 (m, 2H), 6.94 (d, J=7.9Hz, 2H), 6.90 (t, J=9.02Hz, 1H), 3.59 (t, J=5.2Hz, 4H), 3.14 (t, J=5.01Hz, 4H), 1.49 (s, 9H).

[0263] 1-Phenylpiperazine(6)

[0264] The starting carbamate (5) (20.8 g, 80 mmol) was dissolved in MeOH-HCl (1 M, 5 equiv., 400 ml). The reaction mixture was stirred at room temperature for 6 hours, and then the solvent was evaporated. The residue was dissolved in water (200 ml) and then basified with K2CO3 until pH = 9. After this, the water was evaporated, the residue was treated with hot isopropanol (3×150 ml), the precipitate was filtered off and washed twice with isopropanol. Then, the solvent was evaporated to give 9.8 g (76%) of (6) as a yellow oil.

[0265] 1 H NMR (400MHz, CDCl3): δ=7.27-7.33 (m, 2H), 6.91-6.98 (m, 3H), 5.22 (br. S., 1H), 3.31 (t, J=4.92Hz, 4H), 3.21 (t, J=4.92Hz, 4H).

[0266]

[0267] 2-(4-Methylpiperazin-1-yl)-2-phenylacetonitrile (8)

[0268] Sodium bisulfite (26 g, 250 mmol, 1 equiv.) was dissolved in water (250 ml), benzaldehyde (7) (25.5 ml, 250 mmol, 1 equiv.) was added, the mixture was heated to 60°C and then cooled to 35°C. N-methylpiperazine (27.78 ml, 250 mmol, 1 equiv.) was added in one portion and the mixture was stirred at room temperature for 2 hours. A solution of sodium cyanide (12.25 g, 250 mmol) in water (250 ml) was then added with vigorous stirring. After 90 min, the aqueous phase was extracted with CH2Cl2 (3×200 ml), the organic phase was washed with brine, dried over anhydrous Na2SO4 and the solvent was evaporated. The residue was purified by flash chromatography (EtOAc, Rf=0.2) to give 47.82 g (89%) of 8 as an analytically pure yellow solid, melting point=66°C (literature melting point=67-69°C).

[0269] 1 H NMR (400MHz, CDCl3): δ=7.53 (d, J=7.0Hz, 2H), 7.32-7.44 (m, 3H), 4.84 (s, 1H), 2.35-2.79 (m, 8H), 2.29 (s, 3H).

[0270] 2-(4-Methylpiperazin-1-yl)-2-phenylethan-1-amine (9)

[0271] LiAlH4 (42.18 g, 5 equiv., 1.11 mol) was added to a THF solution (1 L), the mixture was cooled to 0°C, and a solution of the starting nitrile (8) (47.8 g, 222 mmol) in THF (250 ml) was added dropwise at 0°C. After all the nitrile was added, the mixture was refluxed for 12 hours, then cooled to 0°C and decomposed by adding 42.2 ml of water, 42.2 ml of 15% NaOH, and 126.6 ml of water in sequence. The mixture was filtered, the precipitate was washed with THF, and the filtrate was evaporated. The residue was purified by flash chromatography (DCM:MeOH(NH3), Rf=0.2) to give 10.9 g (26%) of 9 as a yellow oil.

[0272] 1 H NMR (400MHz, CDCl3): δ=7.29-7.36(m, 3H), 7.21-7.28(m, 2H), 3.31(t, J=6.3H z, 1H), 3.06-3.14 (m, 1H), 2.93-3.02 (m, 1H), 2.34-2.64 (m, 10H), 2.25 (s, 3H).

[0273]

[0274] General procedure for amidation:

[0275] The starting acid (3) (1.1 equiv.) is dissolved in THF (1 M solution), DMF is added dropwise and the solution is cooled to 0°C. Oxalyl chloride (1.2 equiv.) is added dropwise at this temperature and the reaction mixture is stirred at room temperature for 1 hour. The solvent is evaporated and the residue is dissolved in THF (1 M solution). This solution is added dropwise to a solution of the appropriate amine 6 or 9 (1 equiv.) and Et3N (3 equiv.) in THF (1 M solution) at 0°C. After the addition, the reaction mixture is stirred overnight. The THF is evaporated, the residue is treated with water, the aqueous phase is extracted with CH2Cl2, the organic phase is washed with water and brine and dried over anhydrous Na2SO4. The solvent is evaporated and the residue is purified using flash chromatography.

[0276] N-(4-methoxyphenyl)-2-oxo-2-(4-phenylpiperazin-1-yl)acetamide (10):

[0277]

[0278] This compound was prepared using the above procedure, eluent: Hex:EtOAc (3:1, Rf=0.3). Yield: 45% (1.02 g), as an analytically pure white solid, mp=174-178°C.

[0279] 1 H NMR (400MHz, DMSO-d6): δ=9.15 (br.S., 1H), 7.53 (d, J=9.05Hz, 2H), 7.30 (t, J=8.02Hz, 2H), 6.86 -6.99 (m, 5H), 4.46 (t, J=5.13Hz, 4H), 3.89 (t, J=5.2Hz, 4H), 3.82 (s, 3H), 3.28 (t, J=4.92Hz, 4H).

[0280] 13 C NMR (100MHz, DMSO-d6): δ=162.64, 161.25, 155.93, 150.68, 130.97, 129.01 (2C), 1 21.30(2C), 119.61, 116.10(2C), 113.91(2C), 55.17, 48.90, 48.33, 45.55, 40.87.

[0281] HRMS(ESI): For C 19 H 21 N3O3[M+H] + : Calculated value 340.1655, measured value 340.1660.

[0282] N 1 -(4-methoxyphenyl)-N 2 -(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide (11):

[0283]

[0284] This compound was prepared using the above procedure, eluent: DCM:MeOH (10:10): DCM:MeOH (10:1, Rf=0.2). Yield: 43% (960 mg), as an analytically pure white solid, mp=252-256°C.

[0285] 1 H NMR (400MHz, DMSO-d6): δ=10.53 (s, 1H), 8.54 (t, J=5.5Hz, 1H), 7.70 (d, J=9.11Hz, 2H), 7.20-7.37 (m , 5H), 6.89 (d, J=9.03Hz, 2H), 3.65-3.78 (m, 5H), 3.47-3.55 (m, 1H), 2.16-2.46 (m, 8H), 2.09 (s, 3H).

[0286] 13C NMR (100MHz, DMSO-d6): δ=164.12, 159.76, 157.91, 156.08, 136.75, 130.69, 128.61 (2 C), 128.03(2C), 127.51, 121.82(2C), 113.82(2C), 66.67, 55.21, 54.55, 44.89, 40.19.

[0287] HRMS(ESI): For C 22 H 28 N4O3[M+H] + : Calculated value 397.2234, measured value 397.2237.

[0288] Glutamate reuptake assay

[0289] Glutamate uptake assays were performed using a kit from BioIVT and its custom Transflex TM The assay was performed in plates, where 96-well Millipore inserts were seeded with MDCK cells overexpressing hEAAT2 or mock GFP. The assay was performed according to the manufacturer's package insert. Briefly, the transflex assay plates were sterilized and placed in a 37°C 5% CO2 sterile incubator for 20-28 hours prior to the assay.

[0290] Use Ca 2+ and Mg 2+ (pH 7.2-7.4) Hank's balanced salt solution (HBSS-0.14M NaCl, 0.005M KCl, 0.001M CaCl2, 0.0004M MgSO4, 0.0005M MgCl2·6H2O, 0.0003M Na2HPO4·7H2O, 0.0004M KH2PO4, 0.006M D-glucose, 0.004M NaHCO3) was prepared and pre-warmed at 37° C. before use. HBSS was added to the 96-well plate (insert plate) after removing the culture medium and incubated at 37° C. for 5 min.

[0291] Prepare dosing plate by adding 300ul 2% DMSO (DMSO control) solution in HBSS (with or without glutamate) or 2% DMSO solution in HBSS + L-cysteine ​​(1mM) or experimental compounds (D1-D9) at concentrations of 1uM, 3uM and 10uM and known positive control GT951 and reference inhibitor (RI) solution in HBSS + 1μM glutamate. Remove the insert plate from the incubator and place it in the dosing plate, and return the entire device to the incubator for 5min. Then remove the insert plate and place it in a tray filled with ice-cold PBS (pH-7.4, 1μM CaCl2, 1μM MgCl2·6H2O, 1μM MgSO4), and wash the cells 4 times with 150ul ice-cold PBS to remove any excess compounds or glutamate. The insert was removed and placed in a new empty plate, and 100ul of extraction solution (acetonitrile (I): H2O: 50:50) was added, and the device was placed in a shaking bath for 15min. Finally, the insert was centrifuged, and the supernatant and pellet were collected for analysis of glutamate content using LCMS.

[0292] Analyze glutamate in quantitative samples: add 25 μL 100mM sodium carbonate and 25 μL 5% v / v benzoyl chloride IACN to 50 μL sample. After incubation at 4C for 30 min, the sample was centrifuged for 10 min and the supernatant was transferred to an LCMS bottle. The sample was analyzed on an Acquity I-Class UPLC system connected to a Synapt G2Si HDMS mass spectrometer, which was in positive ion mode and had a heated electrospray ionization (ESI) source with a Z spray configuration. LC separation was performed on a Waters Acquity UPLC BEH 1.7μm 2.1×50mm column using a 0.6mL / min A / B 95 / 5 isocratic solvent flow for 6 min, followed by washing and repairing the column. Eluent A was a 0.1% v / v formic acid solution in water, and B was a 0.1% v / v formic acid solution in acetonitrile. The conditions of mass spectrometer are as follows: capillary voltage 0.5kV, sampling cone 40, source offset 80, source 120°C, desolvation temperature 250°C, cone gas 0, desolvation gas 1000L / hr, nebulizer 6.5 bar. The analyzer is operated in resolution mode. Low energy between 100 and 1500Da is collected in a scan time of 0.2 seconds. MSe is collected using a ramp trap collision energy of 20-40V. Mass is extracted from TOF MS TIC using an abs width of 0.05Da. Data are analyzed using Waters MassLynx and Waters Unifi. Quantification is performed using a calibration curve of a true glutamic acid standard.

[0293] animal

[0294] The pharmacokinetic (PK) study of GT951 was conducted at Melior Discovery Services (Exton, PA). The study used 15 male CD-1 mice of 23-50g, and 3 mice were housed in each cage. The PK study of GT467 and GT511 was conducted at Piramal Pharma solutions (Pune, India) according to the approved protocol. The study used 168 male Wistar rats, and 4 were housed in each cage. All animals were raised according to the standard 12-hour light cycle, and water and standard rodent diet were freely available. Food and water were freely available. Animals were not fasted in any part of the study, and animals had been adapted to the animal care facility for seven days before the start of the experiment. During the experiment, the temperature of the feeding room and the operating room was 21-23°C, and the humidity was 40-45% (within the normal range of the care facility). All procedures were completed in accordance with the protocol approved by the Institutional Animal Care and Use Committee (IACUC), including feeding and PK studies.

[0295] Pharmacokinetic evaluation

[0296] For GT951 research, mice were administered 10 mg / kg GT951 via intraperitoneal injection (ip) route, and mice were killed at 0.5, 1, 3, 5 and 8 hours (n=3 / time point), and blood and brain samples were collected. Blood was collected into heparinized tubes via the retroorbital vein before euthanasia, and brain samples were rapidly frozen on dry ice and stored at -80 ° C until further use. Samples were extracted using acetonitrile / protein precipitation. Samples were prepared by adding internal standards (e.g., propranolol), vortexing, and centrifuging the protein precipitate at 2500g for 30 min. 50 μL of supernatant was combined with 500 μL of 1:1:1 0.1% formic acid: acetonitrile: water. The sample was analyzed by LC / MS / MS. The concentration was determined by linear regression analysis from the standard curve to determine the classification. Data are represented by mean ± sem.

[0297] Pharmacokinetic evaluation of GT467 and GT511

[0298] The pharmacokinetic (PK) parameters of GT467 and GT511 were evaluated in rats (n=4 / time point / drug) at a dose of 10 mg / kg (ip and oral) and a dose of 5 mg / kg (iv). Rats were dosed and blood and brain samples were collected at 0.5, 1, 2, 4, 8 and 24 hours. Blood was collected via the sublingual vein under anesthesia and placed in a test tube containing Na2EDTA as an anticoagulant. The plasma portion was separated by centrifugation of the sample at 10,000 rpm for 5 min, and the plasma was transferred to a cryogenic tube and stored at -80°C. The animals were euthanized and the brain was quickly removed on ice and weighed. The brain was homogenized with Milli Q water and the homogenate was stored at -80°C until further use. The samples were bioanalyzed using a Phenomenex synergy C18 column and carbamazepine as internal standards using a SCIEX QTRAP 5500LCMS / MS system. Proteins in the samples were precipitated using a methanol extraction procedure. In addition to the internal standard, drug-free plasma and brain samples were prepared for calibration and quantification standards. All samples were within the detection range of the standard curve. 50 μl of sample was added to 200 μl of internal standard working solution and centrifuged at 10,000 rpm for 5 min. 60 μl of supernatant was added to 140 μl of water and mixed thoroughly before transferring it to LCMS for quantitative analysis.

[0299] Example 1-3: GLT-1 modulators dose-dependently increase glutamate uptake in MDCK cells expressing GLT-1

[0300] Using the pharmacophore obtained from GT951, a small molecule library was designed by combinatorial chemistry and 3822 molecules were modeled. The molecules were docked to the same binding pocket using GOLD docking software and scored with GoldScore. Ten best-ranked molecules were synthesized from the ordered molecules: GT247 (D1), GT251 (D2), GT467 (D3), GT477 (D4), GT487 (D5), GT511 (D6), GT559 (D7), GT562 (D8), and GT619 (D9).

[0301] These compounds were tested using an in vitro transflex plate assay for glutamate uptake. In the transflex plate assay, MDCK cells expressing GLT-1 were treated with three different concentrations of the compounds (1 μM, 3 μM, and 10 μM) and glutamate uptake was measured. The results are shown in Table 1 below and are depicted in Figure 2 middle:

[0302] Table 1

[0303]

[0304] Several compounds were selected to further test the EC of glutamate uptake 50 The glutamate uptake results for these compounds as well as the parent compound GT951 (PC) are shown in Table 2 below:

[0305] Table 2

[0306] Compound <![CDATA[EC of glutamate uptake 50 (nM) <!-- 32 -->]]> GT467 35.1±1.0 GT477 Unstable GT511 3.8±2.2 GT559 9.3±1.4 GT619 78.5±1.0 PC 11.4±1.3

[0307] The results showed that several compounds increased the uptake of glutamate by MDCK cells in a dose-dependent manner. Compounds GT467 (D3) and GT511 (D6) ( Figure 3 ) for further pharmacokinetic and animal testing.

[0308] Examples 1-4: Pharmacokinetic characteristics of GLT-1 modulators

[0309] This study then tested the pharmacokinetic characteristics of GT511 and GT467 in rats by different administration routes.

[0310] Specifically, GT467 or GT511 was administered intraperitoneally (IP), intravenously (IV), or orally (PO) to rats. Figure 4A and Figure 4B The concentrations of the administered compounds in plasma measured at different time points are depicted in Figure 5A and Figure 5B The concentrations of the administered compounds in the brain measured at different time points are depicted in Figure 1. The results show that for GT467, all three types of administration methods resulted in high plasma and brain concentrations. For GT511, intraperitoneal and intravenous administration resulted in higher plasma and brain concentrations than oral administration.

[0311] In addition, pharmacokinetic parameters such as peak concentration (C max ), time to reach peak concentration (T max ), the area under the curve (AUC 0-t ), the area under the curve (AUC 0-∞ ), half-life (t 1 / 2 ), oral clearance (CL / F), observed drug distribution volume (Vz_F_obs) and bioavailability percentage (bioavailability %). The parameters are listed in the following Tables 3-6:

[0312] Table 3: Mean pharmacokinetic parameters of GT467 in plasma after IV, IP and PO administration

[0313] parameter unit IV IP PO <![CDATA[C max ]]> ng / g 307.055 262.370 204.40 <![CDATA[T max ]]> Hr. 0.500 0.500 0.875 <![CDATA[AUC 0-t ]]> hr.ng / ml 315.635 536.768 507.172 <![CDATA[AUC 0-∞ ]]> hr.ng / ml 321.297 555.790 797.848 <![CDATA[t 1 / 2 ]]> Hr. 0.651 1.016 4.764 CL / F ml / hr / kg 16390.725 18146.412 17914.405 Vz_F_obs ml / kg 16170.403 26470.969 95358.274 Bioavailability % - - 85.03 80.34

[0314] Table 4: Mean pharmacokinetic parameters of GT467 brain content after IV, IP and PO administration

[0315] parameter unit IV IP PO <![CDATA[C max ]]> Ng / g 1221.05 2461.17 1173.13 <![CDATA[T max ]]> Hr 0.50 0.50 0.88 <![CDATA[AUC 0-t ]]> hr.ng / g 1959.70 4414.35 2816.80 <![CDATA[AUC 0-∞ ]]> hr.ng / g 2015.59 4442.19 3080.18 <![CDATA[t 1 / 2 ]]> Hr 1.03 1.62 1.81

[0316] Table 5: Mean pharmacokinetic parameters of GT511 in plasma after IV, IP and PO administration

[0317] parameter unit IV IP PO <![CDATA[C max ]]> ng / g 567.22 450.27 42.86 <![CDATA[T max ]]> hr. 0.50 0.63 3.25 <![CDATA[AUC 0-t ]]> hr.ng / ml 919.43 1073.21 321.93 <![CDATA[AUC 0-∞ ]]> hr.ng / ml 995.17 1130.71 399.24 <![CDATA[t 1 / 2 ]]> Hr. 6.08 6.22 5.34 CL / F ml / hr / kg 5178.58 8924.85 30308.07 Vz_F_obs ml / kg 41463.89 79221.20 198882.89 Bioavailability % - - 58.36 17.51

[0318] Table 6: Mean pharmacokinetic parameters of GT511 brain content after IV, IP and PO administration

[0319] parameter unit IV IP PO <![CDATA[C max ]]> Ng / g 370.60 204.10 24.98 <![CDATA[T max ]]> Hr 0.50 0.50 1.38 <![CDATA[AUC 0-t ]]> hr.ng / g 443.23 429.85 183.00 <![CDATA[AUC 0-∞ ]]> hr.ng / g 483.13 467.11 * <![CDATA[t 1 / 2 ]]> Hr 1.52 2.26 *

[0320] Example 1-5: GLT-1 modulators improve locomotion in a Drosophila model of Huntington's disease

[0321] The present study then evaluated the ability of GLT-1 modulators to rescue movement disorders in a fruit fly model of Huntington's disease (also known as the "Htt model").

[0322] The Drosophila Htt model was generated by crossing UAS-Htt (128Q) male flies with e1av-Ga14 virgin female flies. Both Drosophila strains were purchased from the Bloomington Drosophila Stock Center (BDSC, Indiana, USA).

[0323] Huntingtin (128Q) ("Htt(128Q)") is a mutated human gene, expression of which produces a full-length human huntingtin protein with an abnormally long 128 glutamine repeat sequence, which causes Huntington's disease in humans.

[0324] In the resulting UAS-Htt(128Q)X elav-Gal4 offspring flies, expression of the GAL4 protein is driven by the pan-neuronal elav promoter in the fly's neurons. GAL4 in neurons binds to the UAS sequence and drives expression of Htt(128Q), which results in neuron-specific expression of mutant huntingtin protein.

[0325] To verify the expression of the Htt (128Q) human transgene in neurons of UAS-Htt (128Q) X elav-Gal4 flies, RT-qPCR was performed. Brains were dissected from elav-Gal4 X UAS-Htt (128Q) progeny larvae. For control, brains were dissected from larvae expressing elav-Gal4 from the wild-type strain (w1118). After RNA extraction and cDNA conversion, real-time PCR was performed using primers for the Htt (128Q) transgene and reference primers for the housekeeping gene RP49. Only progeny larvae expressing both elav-Gal4 and UAS-Htt (128Q) showed amplification of the Htt (128) primer, thus verifying the expression of Htt (128Q) in the Drosophila Huntington's disease model (HD model).

[0326] The motor ability of the Drosophila HD model is significantly reduced when compared to wild type. Therefore, different concentrations of the compound can be tested to test whether one or more concentrations are neuroprotective.

[0327] To evaluate the rescue of motor impairment in the Drosophila Huntington's disease model (Htt model) by GT467 and GT511, the EC of each compound was determined. 50 , in order to set five concentrations: below EC 50 2 times, lower than EC 50 1x, EC 50 , higher than EC 50 1x and above EC 50 2 times. By transferring the third instar larvae of the flies onto agar plates ( Fig. 6A ) and count the number of grid lines crossed within 30 seconds to perform the motility assay. The motility assay was repeated until the sample size reached 20 larvae for each compound at 5 different concentrations.

[0328] Reference Figure 6B and 6C (WT: Elav x elav + vehicle, Veh: Elav x HTT + vehicle, Numbers: Elav x HTT + indicated concentrations of compounds), treatment with GT467 and GT511 restored the locomotion ability of Huntington's disease model flies. As shown in the figure, concentrations as low as below EC 50 Two-fold and one-fold doses of these compounds were able to fully restore the motor ability of Huntington's disease model flies.

[0329] Example 1-6: GLT-1 modulators improve learning and memory in a Drosophila model of Huntington's disease

[0330] Reference Figures 7A-7D, five groups of flies “WT+Vhe (Elav x elav treated with vehicle)”, “Htt+Veh (Elav x Htt treated with vehicle)”, “Htt+GT467 (Elav x Htt treated with 3.53 nM GT 467)” and “Htt+GT551 (Elav x Htt treated with 0.038 nM GT 511)” were tested for learning and memory in the olfactory learning test.

[0331] Reference Fig. 7A , Drosophila larvae were trained with either a reinforcer solution containing sucrose ("LIN / SUC") or a distilled water control ("LIN / DW"). The trained larvae were then transferred to a dish with the test odorant on one side and the control on the opposite side. The high performers ( Figure 7B ), low performers ( Figure 7C ) and non-performers ( Fig.7D The results showed that the performance of Huntington's disease model larvae was worse than that of their wild-type counterparts, but was significantly improved after treatment with GT 467 and GT 511.

[0332] Example 1-7: GLT-1 modulators increase lifespan in a Drosophila model of Huntington's disease

[0333] Reference Figures 8A-8B In this study, we tested the effects of exemplary GLT-1 modulators on lifespan in a Drosophila model of Huntington's disease.

[0334] Reference Fig. 8A , flies (Htt or wild type) were housed in food vials containing vehicle (DMSO) or exemplary GLT-1 modulators (GT467, GT511). Fly survival was recorded over time.

[0335] Reference Figure 8B Neither of the two exemplary GLT-1 modulators had a negative impact on the lifespan of the flies. One of the two exemplary GLT-1 modulators, GT511, significantly increased the survival rate of fruit flies in the Huntington's disease model until about day 40.

[0336] Example 1-8: GLT-1 modulators rescue motor deficits and improve memory in a mouse model of Huntington's disease

[0337] Reference Figures 9A-9B In this study, an exemplary GLT-1 modulator, GT467, was tested in a mouse model of Huntington's disease.

[0338] The R6 / 2 mouse mimics human Huntington's disease by expressing part of the human HD gene under the human gene promoter element. Figures 9A-9BR6 / 2 mice treated with vehicle ("HTTVeh") or 200 mg / kg ceftriaxone ("HTT CEF") moved significantly shorter distances ( Fig.9A ), and the recognition index scores were significantly lower ( Fig. 9B However, the exemplary GLT-1 modulator GT467 significantly increased the distance ( Fig.9A ) and recognition index score ( Fig. 9B ). These results indicate that GT467 significantly improves the motor activity and ameliorate learning and memory deficits in HD mice.

[0339] Example 2: Novel EAAT2 activators promote glutamate homeostasis and improve cognition without producing impulsive behavior in a rodent model of Parkinson's disease

[0340] Glutamate-induced excitotoxicity has been shown to be one of the pathogenic factors of multiple neurodegenerative diseases, including Parkinson's disease (PD). The excitatory neurotransmitter glutamate is tightly regulated by a network of receptors and transporters in the brain. One such transporter is the excitatory amino acid transporter 2 (EAAT2), which is primarily localized to astrocytes and is responsible for the clearance of approximately 90% of glutamate from synapses. In the case of PD, studies have shown that EAAT2 is downregulated and abnormal activation of presynaptic glutamatergic neurons leads to excitotoxicity and subsequent death of dopaminergic neurons. Dysregulation of dopamine and glutamate neurotransmitters is not only associated with motor and cognitive impairments in PD, but also promotes compulsive and impulsive behaviors. Therefore, the present study hypothesized that a small molecule activator of EAAT2 that can effectively reduce excitotoxicity would be beneficial for treating motor and cognitive impairments without promoting impulsive behaviors. The present study tested GTS467, a novel small molecule activator of EAAT2 according to some embodiments, in a rodent PD model with unilateral lesions. The results of the study demonstrated that GTS467 significantly improved performance on a 5-choice sequential reaction time task and reduced premature impulsive responses and omissions compared to Parkinson's disease animals treated with vehicle. In vitro biochemical analysis of prefrontal cortex and striatum tissue from these treated animals showed increased EAAT2 and decreased postsynaptic glutamate receptor protein expression and normal signaling function. These results suggest that GTS467 could be developed as a novel therapy for the treatment of excitotoxicity in neurodegenerative diseases.

[0341] Example 2-1:

[0342] Parkinson's disorder (PD) is a neurodegenerative disorder characterized by motor and cognitive impairments and a significant loss of dopamine (DA) neurons in the substantia nigra. Dopamine agonists are traditional drugs for the treatment of PD, but they are associated with side effects such as movement disorders and impulse control disorders (ICD). In PD, dysregulation of glutamate neurotransmitters may be a cause of excitotoxicity and ICD. Studies using NMDA antagonists to treat ICD have not been successful and in some cases can aggravate the effects. Excitatory amino acid transporter 2 (EAAT2) regulates glutamate levels by clearing approximately 90% of glutamate from synapses. A new small molecule activator of EAAT2 according to some embodiments, compound GTS467, was tested. It is hypothesized that activators of EAAT2 will contribute to the regulation of glutamate and reduce excitotoxicity associated with PD.

[0343] Example 2-2: Method

[0344] Elevated Plus Maze

[0345] Reference Figure 11-13 In the elevated plus maze test, male PD rats were treated with saline or GTS467 (4 mg / kg). 10 min after treatment, the rats were placed in the center of the elevated plus maze (EPM). The time spent in the closed arm and the open arm was recorded as 5 min. The frequency of entering the open arm and the closed arm was recorded.

[0346] Analysis: Animals that spend more time in the closed arms and less time in the open arms are considered to be displaying anxious behavior.

[0347] Western blot analysis

[0348] The cortex and striatum were collected separately and homogenates were prepared. The homogenates were centrifuged to obtain protein extracts of the membrane and cytoplasmic fractions. The protein of each sample was estimated. The protein lysate was mixed with 6x loading buffer (ratio of 5:1) and heated (95°C for 5 minutes). 20μg of protein was loaded into Tris-Glycine Mini gel and separated at 100mV for 2 hours. The separated protein was transferred to a PVDF membrane. Non-target proteins were blocked with 3% BSA to avoid noise. The membrane was incubated with the primary antibody at 4°C overnight, followed by incubation with the secondary antibody at room temperature for 3 hours. Protein bands were detected using the ECL method. The bands were quantified using Image J software.

[0349] Example 2-2: GTS467 improves cognitive function in PD rats without promoting impulsive behavior

[0350] Reference Fig.14A, the 5CSRTT assay showed that GTS467 reduced impulsivity (as indicated by reduced premature responses).

[0351] Reference Fig. 14B , the 5CSRTT assay showed that GTS467 improved cognitive performance (as indicated by an increased percentage of correct choices).

[0352] Reference Fig. 14C , the 5CSRTT assay showed that GTS467 induced a trend toward fewer omissions compared with saline-treated PD rats.

[0353] Example 2-3: GTS467 does not induce anxiety in PD rats

[0354] Reference Figures 15A-15B , GTS467 did not induce anxiety in PD rats as assessed in the elevated plus maze (EPM) assay, as no significant differences were observed between the groups in the time spent in the open versus closed arms of the EPM.

[0355] Example 2-4: GTS467 treatment enhances EAAT2 expression, which leads to normalization of glutamate neurotransmission and reduction of impulsive behavior

[0356] Reference Figure 16-1 7. GTS467 treatment leads to increased expression of EAAT2 in both the cortex (CRTX) and striatum (STR) of PD rats. GTS467 treatment also causes increased expression of NR2A, 2B, and NR1 at the synaptic level, but not at the extrasynaptic level, which promotes neuronal death.

[0357] Without wishing to be bound by theory, it is hypothesized that the reduction in NR1 may be due to the inhibition of projection neurons in the prefrontal cortex (PFC), which have been reported to be involved in reducing impulsive behavior in PD rats.

[0358] Examples of implementation methods

[0359] The following are examples, the numbering of which should not be construed as designating importance:

[0360] Embodiment 1: A compound of formula (I):

[0361]

[0362] or a salt, solvate, enantiomer, diastereomer, isotopically labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof,

[0363] in:

[0364] A is a key or

[0365] where * is the bond to the carbonyl group;

[0366] R1-R 13 Each is independently selected from H, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 heteroalkyl and C3-C 10 Cycloalkyl, wherein the alkyl, alkoxy, heteroalkyl and cycloalkyl are each independently optionally substituted with at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy;

[0367] R 14 is H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 10 Cycloalkyl and phenyl, wherein the alkyl, alkoxy, heteroalkyl and cycloalkyl are independently optionally substituted with at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy;

[0368] R 15 is phenyl optionally substituted by at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy.

[0369] Embodiment 2: The compound described in Embodiment 1, which prevents, treats and / or improves nervous system disorders.

[0370] Embodiment 3: The compound of embodiment 1, wherein one or more of R1-R5 is C1-C6 alkoxy.

[0371] Embodiment 4: The compound described in Embodiment 1, wherein R 14 is optionally substituted phenyl.

[0372] Embodiment 5: The compound of embodiment 1, wherein the compound is at least one selected from the following:

[0373] N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide (GT467 or GTS467) and

[0374] N-(4-methoxyphenyl)-2-oxo-2-(4-phenylpiperazin-1-yl)acetamide (GT511),

[0375] or a salt, solvate, enantiomer, diastereomer, isotopically labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof.

[0376] Embodiment 6: The compound of embodiment 1, wherein the compound is:

[0377] (R)-N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide or

[0378] (S)-N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide

[0379] or a salt, solvate, isotope-labeled derivative or tautomer thereof.

[0380] Embodiment 7: A method for increasing the activity of a GLT-1 protein, the method comprising contacting the GLT-1 protein with a compound according to any one of embodiments 1-6.

[0381] Embodiment 8: The method described in Embodiment 7, wherein the GLT-1 protein is an isolated protein or a protein expressed in cells.

[0382] Embodiment 9: The method of Embodiment 7, wherein the GLT-1 protein is on the surface of astrocytes.

[0383] Embodiment 10: The method of Embodiment 9, wherein the astrocytes are in the central nervous system (CNS) of the subject.

[0384] Embodiment 11: The method of Embodiment 10, wherein the subject suffers from a disorder associated with elevated extracellular glutamate concentrations at synapses of the CNS, and wherein the method comprises administering to the subject an effective amount of a compound of Embodiment 1.

[0385] Embodiment 12: The method of embodiment 11, wherein the condition associated with excessive extracellular glutamate concentration at the synapses of the CNS includes at least one nervous system disorder selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse, and learning and memory impairment associated with nervous system and neuropsychiatric disorders.

[0386] Embodiment 13: A method for preventing, treating and / or ameliorating a nervous system disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to any one of Embodiments 1-6.

[0387] Embodiment 14: The method described in embodiment 13, wherein the nervous system disorder includes at least one selected from the group consisting of: Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse, and / or learning and memory impairment associated with nervous system and neuropsychiatric disorders.

[0388] Embodiment 15: The method of Embodiment 13, wherein the compound is administered to the subject as a pharmaceutical composition.

[0389] Embodiment 16: The method of Embodiment 15, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0390] Embodiment 17: The method of Embodiment 13, wherein the method further comprises administering an additional therapeutic agent to the subject.

[0391] Embodiment 18: The method of Embodiment 17, wherein said compound and said additional therapeutic agent are co-administered to said subject.

[0392] Embodiment 19: The method of Embodiment 18, wherein the compound and the additional therapeutic agent are co-formulated.

[0393] Embodiment 20: The method of Embodiment 13, wherein the subject is human.

[0394] The features of several embodiments are summarized above so that those skilled in the art can better understand the various aspects of the present disclosure. Those skilled in the art should understand that they can easily use the present disclosure as a basis for designing or modifying other processes and structures to achieve the same purpose and / or achieve the same advantages of the embodiments introduced herein. Those skilled in the art should also recognize that such equivalent structures do not deviate from the spirit and scope of the present disclosure, and they can make various changes, substitutions and variations herein without departing from the spirit and scope of the present disclosure.

Claims

1. A compound of formula (I): or a salt, solvate, enantiomer, diastereomer, isotopically labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof, in: A is a key or where * is the bond to the carbonyl group; R1-R 13 Each is independently selected from H, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 heteroalkyl and C3-C 10 Cycloalkyl, wherein the alkyl, alkoxy, heteroalkyl and cycloalkyl are each independently optionally substituted with at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy; R 14 is H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 10 Cycloalkyl and phenyl, wherein the alkyl, alkoxy, heteroalkyl and cycloalkyl are independently optionally substituted with at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy; R 15 is phenyl optionally substituted by at least one of C1-C6 alkyl, halogen, OH and C1-C6 alkoxy.

2. The compound according to claim 1, which prevents, treats and / or improves nervous system disorders.

3. The compound according to claim 1, wherein one or more of R1-R5 is C1-C6 alkoxy.

4. The compound according to claim 1, wherein R 14 is optionally substituted phenyl.

5. The compound according to claim 1, wherein the compound is at least one selected from the following: N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide (GT467 or GTS467) and N-(4-methoxyphenyl)-2-oxo-2-(4-phenylpiperazin-1-yl)acetamide or a salt, solvate, enantiomer, diastereomer, isotopically labeled derivative, tautomer or geometric isomer thereof, or a mixture thereof.

6. The compound according to claim 1, wherein the compound is: (R)-N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide or (S)-N1-(4-methoxyphenyl)-N2-(2-(4-methylpiperazin-1-yl)-2-phenylethyl)oxalamide or a salt, solvate, isotope-labeled derivative or tautomer thereof.

7. A method for increasing the activity of a GLT-1 protein, the method comprising contacting the GLT-1 protein with a compound according to any one of claims 1 to 6.

8. The method according to claim 7, wherein the GLT-1 protein is an isolated protein or a protein expressed in a cell.

9. The method of claim 7, wherein the GLT-1 protein is on the surface of astrocytes.

10. The method of claim 9, wherein the astrocytes are in the central nervous system (CNS) of a subject.

11. The method of claim 10, wherein the subject suffers from a disorder associated with excessive extracellular glutamate concentrations at synapses of the CNS, and wherein the method comprises administering to the subject an effective amount of a compound of claim 1.

12. The method of claim 11, wherein the condition associated with excessive extracellular glutamate concentrations at synapses of the CNS comprises at least one neurological disorder selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse behaviors, and learning and memory impairments associated with neurological and neuropsychiatric disorders.

13. A method for preventing, treating and / or ameliorating a nervous system disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6.

14. The method of claim 13, wherein the nervous system disorder comprises at least one selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, epilepsy, schizophrenia, compulsive and impulsive drug and alcohol abuse behaviors, and / or learning and memory impairments associated with nervous system and neuropsychiatric disorders.

15. The method of claim 13, wherein the compound is administered to the subject as a pharmaceutical composition.

16. The method of claim 15, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

17. The method of claim 13, wherein the method further comprises administering to the subject an additional therapeutic agent.

18. The method of claim 17, wherein the compound and the additional therapeutic agent are co-administered to the subject.

19. The method of claim 18, wherein the compound and the additional therapeutic agent are co-formulated.

20. The method of claim 13, wherein the subject is a human.

Citation Information

Patent Citations

  • Extending the duration of drug release within the stomach during the fed mode

    US20020051820A1

  • Extending the duration of drug release within the stomach during the fed mode

    US20030039688A1

  • Pharmacological inducement of the fed mode for enhanced drug administration to the stomach

    US20030044466A1

  • Optimal polymer mixtures for gastric retentive tablets

    US20030104053A1

  • Shell-and-core dosage form approaching zero-order drug release

    US20030104062A1